<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23092" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperaldosteronism</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dominguez</surname>
            <given-names>Alejandro</given-names>
          </name>
          <aff>Campbell University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muppidi</surname>
            <given-names>Vijayadershan</given-names>
          </name>
          <aff>Indiana University health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Sonu</given-names>
          </name>
          <aff>Campbell University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alejandro Dominguez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vijayadershan Muppidi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sonu Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23092.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperaldosteronism is a condition characterized by the excess production of aldosterone by the adrenal glands, which leads to hypertension that is often resistant to standard treatments. Hyperaldosteronism presents initially as refractory hypertension in relatively young patients but&#x000a0;is frequently undiagnosed.&#x000a0;Hyperaldosteronism can be primary, originating from the adrenal gland itself, or secondary, resulting from external factors that increase renin production. Both forms present similarly and are differentiated through laboratory testing and diagnostic studies.&#x000a0;</p>
        <p>Initial screening for hyperaldosteronism is recommended for all patients newly diagnosed with hypertension, especially if their hypertension is difficult to manage medically or they have adrenal nodules. Screening is relatively simple, requiring only serum levels of renin and aldosterone. A serum aldosterone level of more than 20 ng/dL or an aldosterone-to-renin ratio of more than 20:1 is considered diagnostic of hyperaldosteronism by most experts.</p>
        <p>Additionally, lateralization studies can differentiate between unilateral and bilateral diseases, which require different treatment approaches. Primary hyperaldosteronism caused by a unilateral abnormally functioning adrenal gland is best treated with a complete unilateral laparoscopic or robotic adrenalectomy. Patients with bilateral disease and nonsurgical candidates are best managed medically with mineralocorticoid receptor antagonists such as spironolactone and eplerenone. Accurate diagnosis and differentiation are crucial for selecting the appropriate treatment approach, whether surgical or medical, to improve patient outcomes.</p>
        <p>This activity reviews the etiologies of hyperaldosteronism and provides clinicians with guidance on selecting appropriate diagnostic tests, managing the condition, and fostering effective collaboration among interprofessional healthcare clinicians to enhance patient care and outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients at high risk for hyperaldosteronism, particularly those with refractory hypertension or adrenal nodules.</p></list-item><list-item><p>Implement appropriate diagnostic strategies, including lateralization studies, to determine the need for surgical versus medical management.</p></list-item><list-item><p>Select the appropriate diagnostic tests, such as renin and aldosterone measurements, to accurately diagnose hyperaldosteronism.</p></list-item><list-item><p>Collaborate with interdisciplinary healthcare teams to ensure comprehensive care, optimize treatment outcomes, and enhance patient&#x000a0;care&#x000a0;for hyperaldosteronism.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23092&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23092">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23092.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Aldosterone is a mineralocorticoid hormone that promotes sodium (salt) and water (fluid) retention, ultimately raising blood pressure.<xref ref-type="bibr" rid="article-23092.r1">[1]</xref>&#x000a0;Aldosterone also increases urinary potassium excretion, resulting in hypokalemia.<xref ref-type="bibr" rid="article-23092.r1">[1]</xref>&#x000a0;It&#x000a0;is secreted by the zona glomerulosa&#x02014;the outermost layer of the adrenal cortex.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref> Excess production of aldosterone is referred to as hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref> This condition typically presents initially as hypertension, which can range from mild to severe and resistant to treatment. Often, the underlying hyperaldosteronism responsible for the hypertension goes undiagnosed.&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/17346">Physiology, Aldosterone</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r1">[1]</xref>&#x000a0;</p>
        <p>Hyperaldosteronism can be of primary or secondary origin.&#x000a0;Although both forms present similarly, they are differentiated through laboratory testing and diagnostic studies. Primary hyperaldosteronism is characterized by low plasma renin concentrations, usually less than 1 ng/mL/h, and elevated serum aldosterone levels, typically more than 20 ng/dL, due to inappropriate autonomous hypersecretion of adrenal aldosterone. Secondary hyperaldosteronism results from excessive renin production and activity due to various conditions, including renal artery stenosis, left heart failure, liver failure with ascites, cor pulmonale, pregnancy, renin-secreting tumors, excessive licorice ingestion, renal tubular acidosis, nutcracker syndrome, kidney failure, and genetic conditions such as Bartter and Gitelman syndromes.</p>
        <p>The initial definitive laboratory measurements to diagnose hyperaldosteronism include plasma renin concentration and activity, serum aldosterone levels, and the aldosterone-to-renin ratio.&#x000a0;Patients with hyperaldosteronism, especially women, often experience significant diagnostic delays, with more than one-third of patients waiting over 5 years to receive a correct diagnosis.<xref ref-type="bibr" rid="article-23092.r3">[3]</xref>&#x000a0;Please&#x000a0;see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/23093">Primary Hyperaldosteronism</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref></p>
        <p>Routine screening for hyperaldosteronism (serum aldosterone &#x0003e;20 ng/dL or an aldosterone-to-renin ratio &#x0003e;20:1) is recommended for all patients newly diagnosed with hypertension, particularly those unresponsive to standard antihypertensive medications.<xref ref-type="bibr" rid="article-23092.r3">[3]</xref><xref ref-type="bibr" rid="article-23092.r4">[4]</xref><xref ref-type="bibr" rid="article-23092.r5">[5]</xref><xref ref-type="bibr" rid="article-23092.r6">[6]</xref> Understanding the diagnosis and differentiation of hyperaldosteronism is essential to determine the appropriate treatment, whether surgical for unilateral primary hyperaldosteronism or medical for bilateral adrenal disease and secondary hyperaldosteronism.</p>
      </sec>
      <sec id="article-23092.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The underlying cause of the excess aldosterone production differentiates primary from secondary hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r7">[7]</xref>&#x000a0;High serum aldosterone with low renin levels suggests primary hyperaldosteronism, while high plasma renin indicates secondary disease.<xref ref-type="bibr" rid="article-23092.r7">[7]</xref></p>
        <p>
<bold>Primary Hyperaldosteronism</bold>
</p>
        <p>Primary hyperaldosteronism, also known as Conn syndrome, was first described in 1956 and is caused by excessive autonomous aldosterone production by the adrenal gland, specifically the zona glomerulosa.<xref ref-type="bibr" rid="article-23092.r8">[8]</xref>&#x000a0;In&#x000a0;90% of patients, primary hyperaldosteronism most often presents as a unilateral hypersecreting glandular adrenal tumor, but it may also present as bilateral adrenal hyperplasia. "Primary hyperaldosteronism" is the preferred terminology, whether due to a unilateral primary adenoma, which is treated surgically, or bilateral idiopathic adrenal hyperplasia, managed medically. Please see the companion StatPearls' reference resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/17227">Physiology, Adrenal Gland</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19895">Conn Syndrome</ext-link>" for more information.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="13275846">[7</ext-link><xref ref-type="bibr" rid="article-23092.r9">]</xref><xref ref-type="bibr" rid="article-23092.r8">[8]</xref></p>
        <p>Infrequent forms of primary hyperaldosteronism include unilateral adrenal hyperplasia, ectopic aldosterone-secreting tumors (usually in the kidneys or ovaries), aldosterone-producing adrenocortical carcinomas, and familial hyperaldosteronism, with type I being the most common.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref><xref ref-type="bibr" rid="article-23092.r9">[9]</xref>&#x000a0;Newer data suggest that the incidence of bilateral adrenal hyperplasia may account for up to 75% of all cases of primary hyperaldosteronism.</p>
        <p>Genetic causes of primary hyperaldosteronism are rare. However, the following 3 types of&#x000a0;familial hyperaldosteronism are usually described in the literature:</p>
        <list list-type="bullet">
          <list-item>
            <p>Type I familial primary hyperaldosteronism: This is caused by a 2-part chimeric gene (<italic toggle="yes">CYP11B1/CYP11B2</italic>) with a regulatory segment from 11&#x003b2;-hydroxylase and a synthesis portion from aldosterone synthase.<xref ref-type="bibr" rid="article-23092.r10">[10]</xref>&#x000a0;Under stimulation of ACTH, aldosterone synthase is activated and aldosterone production increases. Type I familial primary hyperaldosteronism is a rare autosomal dominant heritable disorder associated with increased production of&#x000a0;18-oxocortisol and 18-hydroxycortisol.<xref ref-type="bibr" rid="article-23092.r10">[10]</xref>&#x000a0;The condition&#x000a0;is glucocorticoid-remediable.<xref ref-type="bibr" rid="article-23092.r10">[10]</xref><xref ref-type="bibr" rid="article-23092.r11">[11]</xref><xref ref-type="bibr" rid="article-23092.r12">[12]</xref><xref ref-type="bibr" rid="article-23092.r13">[13]</xref>&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19895">Conn Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Type II&#x000a0;familial primary hyperaldosteronism: This is&#x000a0;linked to chromosomes 7p22 and 11q13, resulting in the histological equivalent of adrenal hyperplasia.<xref ref-type="bibr" rid="article-23092.r10">[10]</xref>&#x000a0;This type of&#x000a0;familial primary hyperaldosteronism is not glucocorticoid-remediable.<xref ref-type="bibr" rid="article-23092.r10">[10]</xref><xref ref-type="bibr" rid="article-23092.r11">[11]</xref><xref ref-type="bibr" rid="article-23092.r12">[12]</xref><xref ref-type="bibr" rid="article-23092.r13">[13]</xref>&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19895">Conn Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Type III&#x000a0;familial primary hyperaldosteronism: This occurs due to a&#x000a0;T158A mutation in a potassium channel gene, <italic toggle="yes">KCNJF</italic>, which increases cellular calcium levels, leading to increased aldosterone production by the glomerulosa cells.<xref ref-type="bibr" rid="article-23092.r10">[10]</xref><xref ref-type="bibr" rid="article-23092.r12">[12]</xref><xref ref-type="bibr" rid="article-23092.r14">[14]</xref>&#x000a0;Type III familial primary hyperaldosteronism is not glucocorticoid-remediable.<xref ref-type="bibr" rid="article-23092.r10">[10]</xref><xref ref-type="bibr" rid="article-23092.r11">[11]</xref><xref ref-type="bibr" rid="article-23092.r12">[12]</xref><xref ref-type="bibr" rid="article-23092.r13">[13]</xref>&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19895">Conn Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Secondary Hyperaldosteronism</bold>
</p>
        <p>Secondary hyperaldosteronism occurs due to excessive and inappropriate activation of the renin-angiotensin-aldosterone system (RAAS). Any reduction in renal blood flow can stimulate the RAAS, resulting in increased aldosterone production and secretion. This overproduction can result from a renin-producing tumor, hyperkalemia from chronic renal failure, or renal artery stenosis, as well as generalized edematous disorders like left ventricular heart failure, pregnancy, cor pulmonale, Bartter or Gitelman syndrome, nutcracker syndrome, hepatic cirrhosis with ascites, obstructive sleep apnea, or nephrotic syndrome. Please see the companion StatPearls' reference resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/28375">Physiology, Renin Angiotensin System</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/18152">Bartter Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r15">[15]</xref><xref ref-type="bibr" rid="article-23092.r16">[16]</xref></p>
        <p>In some cases, such as cardiac failure, aldosterone production may be within the normal range; however, its metabolism by the liver may be reduced due to decreased hepatic blood flow, resulting in elevated serum levels of aldosterone. Patients with secondary hyperaldosteronism tend to have higher blood pressures and greater levels of serum aldosterone than those with primary disease.</p>
      </sec>
      <sec id="article-23092.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Primary hyperaldosteronism can be seen in at least 10% of all patients with hypertension.<xref ref-type="bibr" rid="article-23092.r5">[5]</xref><xref ref-type="bibr" rid="article-23092.r17">[17]</xref><xref ref-type="bibr" rid="article-23092.r18">[18]</xref><xref ref-type="bibr" rid="article-23092.r19">[19]</xref>&#x000a0;The incidence of primary hyperaldosteronism increases with the severity of the associated hypertension.<xref ref-type="bibr" rid="article-23092.r20">[20]</xref>&#x000a0;The prevalence is over 20% in patients with resistant hypertension, especially in those younger than 40 or those who exhibit hypokalemia.<xref ref-type="bibr" rid="article-23092.r20">[20]</xref><xref ref-type="bibr" rid="article-23092.r21">[21]</xref><xref ref-type="bibr" rid="article-23092.r22">[22]</xref><xref ref-type="bibr" rid="article-23092.r23">[23]</xref><xref ref-type="bibr" rid="article-23092.r24">[24]</xref><xref ref-type="bibr" rid="article-23092.r25">[25]</xref>&#x000a0;Earlier studies grossly underestimated the incidence of hyperaldosteronism due to differences in patient selection, diagnostic methods, definitions of hypertension, and a general failure to test patients who met the currently recommended criteria for screening.<xref ref-type="bibr" rid="article-23092.r23">[23]</xref><xref ref-type="bibr" rid="article-23092.r24">[24]</xref><xref ref-type="bibr" rid="article-23092.r26">[26]</xref><xref ref-type="bibr" rid="article-23092.r27">[27]</xref><xref ref-type="bibr" rid="article-23092.r28">[28]</xref><xref ref-type="bibr" rid="article-23092.r29">[29]</xref><xref ref-type="bibr" rid="article-23092.r30">[30]</xref></p>
        <p>Secondary hyperaldosteronism is diagnosed less often than primary hyperaldosteronism. Both primary and secondary hyperaldosteronism are more prevalent in women. Africans and Black Americans tend to have a higher prevalence of hyperaldosteronism than the general population, particularly idiopathic bilateral adrenal hyperplasia.<xref ref-type="bibr" rid="article-23092.r31">[31]</xref><xref ref-type="bibr" rid="article-23092.r32">[32]</xref></p>
      </sec>
      <sec id="article-23092.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Aldosterone is the primary mineralocorticoid in the body, acting on the epithelial sodium channels in the collecting tubules and causing sodium reabsorption.&#x000a0;This creates a negative potential in the tubular lumen, leading to the movement of cations, primarily potassium and hydrogen ions, into the tubular lumen to maintain electrical neutrality. This process results in hypokalemia, aciduria, and metabolic alkalosis.&#x000a0;The increased reabsorption of sodium and water leads to intravascular volume expansion and hypertension.<xref ref-type="bibr" rid="article-23092.r26">[26]</xref>&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/17346">Physiology, Aldosterone</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r1">[1]</xref>&#x000a0;</p>
        <p>Aldosterone production is usually confined to the zona glomerulosa of the adrenal glands, where aldosterone synthase enzymatically converts 11-deoxycorticosterone to aldosterone, a process mediated by serum potassium and angiotensin II levels.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref>&#x000a0;ACTH also stimulates aldosterone production, contributing to the observed diurnal pattern of hormone secretion.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref>&#x000a0;</p>
        <p>
<bold>Primary Hyperaldosteronism</bold>
</p>
        <p>Primary hyperaldosteronism occurs due to excess autonomous aldosterone production by&#x000a0;the adrenal gland.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref> The most common causes of primary hyperaldosteronism are idiopathic bilateral adrenal hyperplasia and a hypersecreting adenomatous tumor in the zona glomerulosa, both of which can directly cause an inappropriate increase in serum aldosterone. These patients are often asymptomatic but typically present with hypertension that is difficult to control; hypokalemia may also be present.<xref ref-type="bibr" rid="article-23092.r27">[27]</xref>&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19895">Conn Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r8">[8]</xref></p>
        <p>Both primary and secondary hyperaldosteronism can present with a broad clinical range.<xref ref-type="bibr" rid="article-23092.r26">[26]</xref>&#x000a0;Approximately&#x000a0;one-fifth of all patients with primary hyperaldosteronism will also demonstrate reduced glucose tolerance from their hypokalemia, even though the overall incidence of diabetes is the same as in the general population.<xref ref-type="bibr" rid="article-23092.r33">[33]</xref><xref ref-type="bibr" rid="article-23092.r34">[34]</xref><xref ref-type="bibr" rid="article-23092.r35">[35]</xref><xref ref-type="bibr" rid="article-23092.r36">[36]</xref>&#x000a0;Metabolic alkalosis may also be present.</p>
        <p>The renal response to decreased vascular perfusion or increased serum renin levels causes secondary hyperaldosteronism. The juxtaglomerular cells detect this reduction in renal blood flow and release renin, which activates the renin-angiotensin system and synthesizes angiotensin II. Angiotensin II increases systemic blood pressure by enhancing proximal tubular sodium reabsorption, causing generalized vasoconstriction, and stimulating aldosterone secretion. The net effect is sodium retention, increased intravascular volume, high renin levels, elevated blood pressure, and secondary hyperaldosteronism.</p>
        <p>The following 3 pathophysiological features of primary hyperaldosteronism, as originally described by Conn&#x000a0;et al in 1964, remain the mainstay of the diagnostic approach:</p>
        <list list-type="bullet">
          <list-item>
            <p>Autonomous aldosterone production lowers plasma renin, producing a high aldosterone-to-renin ratio and a low serum renin level.</p>
          </list-item>
          <list-item>
            <p>Reduced renin response to stimulation (eg, administering an angiotensin-converting enzyme [ACE] inhibitor).</p>
          </list-item>
          <list-item>
            <p>Lack of suppression of aldosterone production by volume expansion or salt loading, usually tested by an intravenous saline infusion or significant dietary salt ingestion.<xref ref-type="bibr" rid="article-23092.r8">[8]</xref><xref ref-type="bibr" rid="article-23092.r20">[20]</xref><xref ref-type="bibr" rid="article-23092.r37">[37]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Secondary Hyperaldosteronism</bold>
</p>
        <p>Secondary hyperaldosteronism occurs due to the excess stimulation of the RAAS. While it can result from the physiological state of transient RAAS activation (eg, hypovolemia), it is also seen in pathological states of sustained activation of the system, including the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Renal artery stenosis (eg, atherosclerosis or fibromuscular dysplasia) decreases kidney blood flow, stimulates a false sense of hypovolemia, and increases aldosterone secretion.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Left-sided congestive heart failure and cor pulmonale cause a decrease in cardiac output, leading to stimulation of aldosterone production.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In&#x000a0;patients with cirrhosis, nephrotic syndrome, and ascites, the reduction&#x000a0;in circulating fluid volume leads to decreased perfusion through the kidneys and results in increased aldosterone secretion.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Poor hepatic blood flow causes secondary hyperaldosteronism due to decreased liver metabolism of aldosterone, resulting in higher serum levels even though adrenal production of the hormone is in the normal range.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>RAAS can also be activated by a renin-producing tumor in the juxtaglomerular cells, although this is a very uncommon finding. Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/18152">Bartter Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r16">[16]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23092.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathology is not typically used as a standard tool for diagnosing hyperaldosteronism, although immunohistochemical staining can be helpful. Up to one-third of aldosterone-producing adrenal adenomas may show hyperplasia of the zona glomerulosa. This hyperplasia can be localized to a broad area or present as generalized thickening throughout the cortex. Extensions of the cortical glomerulosa may also appear to penetrate centrally.</p>
        <p>Idiopathic bilateral hyperaldosteronism exhibits a variable histological appearance, ranging from nearly normal-appearing hyperplasia to micronodular and macronodular patterns. Immunohistochemical staining of cytochrome P450 (CYP)-11B2 in aldosterone-producing adenomas has proven highly valuable. This staining helps differentiate among the various types and subtypes of adenomas, micronodules, and aldosterone-producing cell clusters, with CYP-11B1 stains being positive for cortisol-producing cells.<xref ref-type="bibr" rid="article-23092.r38">[38]</xref></p>
      </sec>
      <sec id="article-23092.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Clinical Features of Hyperaldosteronism</bold>
</p>
        <p>The clinical features of hyperaldosteronism can vary depending on the severity and may sometimes be asymptomatic. Resistant hypertension is the most common presenting symptom for these patients, especially when associated with hypokalemia. A characteristic presentation of hyperaldosteronism is a young woman who remains inadequately controlled on 3 or more antihypertensive medications.<xref ref-type="bibr" rid="article-23092.r27">[27]</xref>&#x000a0;Other common symptoms include fatigue, headache, weakness, abdominal distension, ileus, polyuria, polydipsia, and nephrogenic diabetes insipidus secondary to hypokalemia.&#x000a0;</p>
        <p>Blood pressure in hyperaldosteronism can range from normotensive to severe hypertension and is often refractory to standard antihypertensive treatments. Hypertension in aldosteronism is primarily caused by sodium reabsorption, volume expansion, and increased peripheral vascular resistance.<xref ref-type="bibr" rid="article-23092.r26">[26]</xref>&#x000a0;Symptoms are typically a result of moderate to severe hypertension or secondary to hypokalemia. High blood pressure may lead to headaches, dizziness, vision problems, chest pain, and dyspnea. Additionally, antidiuretic hormone resistance in the renal tubules due to hypokalemia can contribute to diabetes insipidus in aldosteronism.<xref ref-type="bibr" rid="article-23092.r26">[26]</xref></p>
        <p>Hypokalemia may lead to muscle weakness, fatigue, cardiac palpitations, cramps, polydipsia, and polyuria due to nephrogenic diabetes insipidus. A thorough medical history should also be obtained, as there may be a family history of hypertension or early cardiovascular events, such as stroke.<xref ref-type="bibr" rid="article-23092.r26">[26]</xref></p>
        <p>Patients with secondary hyperaldosteronism may present with varying blood pressure levels, but most will have some degree of hypertension. Conditions such as renal artery stenosis and coarctation of the aorta also contribute to elevated blood pressure.&#x000a0;Please see the companion StatPearls' reference resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/28335">Renal Artery Stenosis</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28613663">Coarctation of the Aorta,</ext-link>" for more information.<xref ref-type="bibr" rid="article-23092.r39">[39]</xref><xref ref-type="bibr" rid="article-23092.r40">[40]</xref>&#x000a0;</p>
        <p>Hypovolemia can occur in patients using diuretics or with heart failure, cirrhosis, or nephrotic syndrome. Gitelman and Bartter syndromes often present with mild hypotension.<xref ref-type="bibr" rid="article-23092.r16">[16]</xref><xref ref-type="bibr" rid="article-23092.r26">[26]</xref><xref ref-type="bibr" rid="article-23092.r41">[41]</xref>&#x000a0;Please see the companion StatPearls' reference resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/18152">Bartter Syndrome</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22254">Gitelman Syndrome</ext-link>" for more information.<xref ref-type="bibr" rid="article-23092.r16">[16]</xref><xref ref-type="bibr" rid="article-23092.r41">[41]</xref></p>
        <p>Although no specific physical signs are diagnostic of hyperaldosteronism, long-term hypertension can lead to left ventricular hypertrophy, which may manifest as an S4 heart sound due to the passage of blood into a stiff and noncompliant left ventricle. Other signs of chronic hypertension may also be observed.</p>
        <p>
<bold>Risk Factors for Hyperaldosteronism</bold>
</p>
        <p>Factors associated with an increased risk for hyperaldosteronism include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Family history of hypertension or cardiovascular events at young ages</p>
          </list-item>
          <list-item>
            <p>Hypertension, diagnosed before age 40</p>
          </list-item>
          <list-item>
            <p>Hypokalemia, whether spontaneous or induced by thiazide diuretics</p>
          </list-item>
          <list-item>
            <p>Incidental discovery of an adrenal adenoma in a patient with hypertension, particularly if the blood pressure is difficult to control</p>
          </list-item>
          <list-item>
            <p>Resistant or intractable hypertension, which remains poorly controlled despite the use of 3 or more standard antihypertensive medications, including a diuretic&#x000a0;<xref ref-type="bibr" rid="article-23092.r20">[20]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23092.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Hyperaldosteronism Screening</bold>
</p>
        <p>Screening for hyperaldosteronism is recommended for all patients newly diagnosed with hypertension, especially those with early-onset significant hypertension, hypokalemia, resistant or intractable high blood pressure, obstructive sleep apnea, or an adrenal mass. The high prevalence of hyperaldosteronism among hypertensive individuals, with many cases going undiagnosed, underscores the importance of such screening.<xref ref-type="bibr" rid="article-23092.r5">[5]</xref><xref ref-type="bibr" rid="article-23092.r6">[6]</xref><xref ref-type="bibr" rid="article-23092.r23">[23]</xref><xref ref-type="bibr" rid="article-23092.r27">[27]</xref><xref ref-type="bibr" rid="article-23092.r42">[42]</xref><xref ref-type="bibr" rid="article-23092.r43">[43]</xref><xref ref-type="bibr" rid="article-23092.r44">[44]</xref><xref ref-type="bibr" rid="article-23092.r45">[45]</xref><xref ref-type="bibr" rid="article-23092.r46">[46]</xref><xref ref-type="bibr" rid="article-23092.r47">[47]</xref>&#x000a0;</p>
        <p>Hyperaldosteronism screening is grossly underutilized, with only about 3% of patients with resistant hypertension receiving appropriate testing.<xref ref-type="bibr" rid="article-23092.r30">[30]</xref><xref ref-type="bibr" rid="article-23092.r48">[48]</xref><xref ref-type="bibr" rid="article-23092.r49">[49]</xref>&#x000a0;Frequent misdiagnosis of hyperaldosteronism is due to several factors, including a general lack of awareness about its prevalence, high levels of subclinical hyperaldosteronism in the population, complexity of confirmatory testing, absence of standardized screening protocols, high prevalence of atypical presentations, and difficulties in interpreting test results.<xref ref-type="bibr" rid="article-23092.r23">[23]</xref><xref ref-type="bibr" rid="article-23092.r50">[50]</xref><xref ref-type="bibr" rid="article-23092.r51">[51]</xref><xref ref-type="bibr" rid="article-23092.r52">[52]</xref></p>
        <p>Screening for hyperaldosteronism typically involves a simple plasma renin and aldosterone blood test. A low renin level combined with an aldosterone-to-renin ratio of more than 20 or a plasma aldosterone concentration (PAC) of more than 20 ng/dL commonly indicates possible hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref><xref ref-type="bibr" rid="article-23092.r47">[47]</xref><xref ref-type="bibr" rid="article-23092.r53">[53]</xref>&#x000a0;A ratio of 30 or more is highly suggestive of the diagnosis. Confirmatory testing, computed tomography (CT) imaging, and selective bilateral adrenal venous sampling may then be performed.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref><xref ref-type="bibr" rid="article-23092.r47">[47]</xref><xref ref-type="bibr" rid="article-23092.r53">[53]</xref><xref ref-type="bibr" rid="article-23092.r54">[54]</xref>&#x000a0;Please&#x000a0;see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/23093">Primary Hyperaldosteronism</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref></p>
        <p>
<bold>Laboratory Findings Suggestive of Hyperaldosteronism</bold>
</p>
        <p>The aldosterone-to-renin ratio has long been considered a reliable screening test for hyperaldosteronism, but results may be somewhat variable in certain situations.<xref ref-type="bibr" rid="article-23092.r20">[20]</xref><xref ref-type="bibr" rid="article-23092.r55">[55]</xref><xref ref-type="bibr" rid="article-23092.r56">[56]</xref>&#x000a0;The levels should be drawn in the morning, and any interfering drugs should be eliminated, but this is not always safe or practical.<xref ref-type="bibr" rid="article-23092.r20">[20]</xref><xref ref-type="bibr" rid="article-23092.r27">[27]</xref><xref ref-type="bibr" rid="article-23092.r57">[57]</xref>&#x000a0;The aldosterone-to-renin ratio can be affected by posture, diurnal variations, electrolytes (eg, potassium levels), and several medications other than anti-hypertensives, including various antidepressants, antihistamines, dopaminergic meds, estrogens, licorice, and nonsteroidal anti-inflammatory drugs (NSAIDs).<xref ref-type="bibr" rid="article-23092.r20">[20]</xref><xref ref-type="bibr" rid="article-23092.r27">[27]</xref><xref ref-type="bibr" rid="article-23092.r57">[57]</xref><xref ref-type="bibr" rid="article-23092.r58">[58]</xref><xref ref-type="bibr" rid="article-23092.r59">[59]</xref><xref ref-type="bibr" rid="article-23092.r60">[60]</xref>&#x000a0;Other laboratory findings may demonstrate hypokalemia, mild hypernatremia, and mild hypomagnesemia, but these are not diagnostic.<xref ref-type="bibr" rid="article-23092.r61">[61]</xref><xref ref-type="bibr" rid="article-23092.r62">[62]</xref><xref ref-type="bibr" rid="article-23092.r63">[63]</xref></p>
        <p>Hypokalemia has historically been considered a hallmark finding closely associated with hyperaldosteronism but is now recognized as a relatively rare occurrence.<xref ref-type="bibr" rid="article-23092.r20">[20]</xref><xref ref-type="bibr" rid="article-23092.r64">[64]</xref><xref ref-type="bibr" rid="article-23092.r65">[65]</xref><xref ref-type="bibr" rid="article-23092.r66">[66]</xref>&#x000a0;Therefore, the lack of hypokalemia should not be used to exclude a diagnosis of hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r20">[20]</xref>&#x000a0;Current estimates indicate that less than 37% of those with confirmed primary hyperaldosteronism will demonstrate low serum potassium levels.<xref ref-type="bibr" rid="article-23092.r32">[32]</xref>&#x000a0;Metabolic alkalosis is frequently observed in hyperaldosteronism due to the net loss of hydrogen ions in the urine from aldosterone-induced renal sodium retention, in which hydrogen ions are excreted in exchange for sodium.<xref ref-type="bibr" rid="article-23092.r67">[67]</xref>&#x000a0;The historically well-documented association of hyperaldosteronism with hypokalemia has been observed in fewer than 40% of patients in published studies.</p>
        <p>The role of the 24-hour urine collection in hyperaldosteronism is controversial, although it can detect inappropriate potassium wasting, defined as &#x0003e;30 mEq/d.<xref ref-type="bibr" rid="article-23092.r68">[68]</xref><xref ref-type="bibr" rid="article-23092.r69">[69]</xref><xref ref-type="bibr" rid="article-23092.r70">[70]</xref>&#x000a0;This test can be useful in evaluating the role of extrarenal losses and diuretic abuse in hypokalemia, especially when the increase in aldosterone is barely detectable to mild.&#x000a0;A urinary aldosterone-to-creatinine ratio has been suggested to facilitate the initial diagnosis of primary hyperaldosteronism by using an aldosterone-to-creatinine ratio of 3 ng aldosterone&#x000a0;per 1 mg creatinine as the threshold.<xref ref-type="bibr" rid="article-23092.r71">[71]</xref>&#x000a0;The validity of this test has not yet been established or fully verified.<xref ref-type="bibr" rid="article-23092.r71">[71]</xref></p>
        <p>
<bold>Primary Hyperaldosteronism Diagnostic Evaluation</bold>
</p>
        <p>In primary hyperaldosteronism, plasma renin activity (PRA) is less than 1 ng/mL/h, and the plasma renin concentration is either very low or undetectable. Excess aldosterone originates from the zona glomerulosa itself and not an extrinsic pathway. Therefore, a morning serum aldosterone-to-renin ratio of more than 20:1 indicates a renin-independent etiology consistent with primary hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref></p>
        <p>The PAC/PRA ratio is a confirmatory test for primary hyperaldosteronism. Most studies support an elevated PAC/PRA ratio of more than 30:1 and a&#x000a0;PAC of more than 20 ng/dL with a sensitivity and specificity of more than 90% as being diagnostic for primary hyperaldosteronism. However, a PAC/PRA ratio greater than 20:1 and a&#x000a0;PAC of more than 15 ng/dL are reportedly sufficient to support the diagnosis.<xref ref-type="bibr" rid="article-23092.r72">[72]</xref><xref ref-type="bibr" rid="article-23092.r73">[73]</xref> Please&#x000a0;see the companioin StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/23093">Primary Hyperaldosteronism</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref></p>
        <p>
<bold>Secondary Hyperaldosteronism Diagnostic Evaluation</bold>
</p>
        <p>In secondary hyperaldosteronism, both the plasma renin concentration and PRA levels are increased, as renin is the primary stimulator for the excess production of aldosterone, and the serum aldosterone-to-renin ratio will, therefore, be much lower than in primary hyperaldosteronism. These levels are usually measured in the morning after patients have been out of bed. The results are more accurate when the labs are drawn at least 2 hours after the patient is out of bed and spends at least 5 minutes sitting. The serum aldosterone-to-renin ratio will be less than 20:1.&#x000a0;PRA, plasma renin concentration, and renin levels increase in secondary hyperaldosteronism, but the PAC/PRA ratio is less than in primary hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r27">[27]</xref><xref ref-type="bibr" rid="article-23092.r72">[72]</xref><xref ref-type="bibr" rid="article-23092.r73">[73]</xref><xref ref-type="bibr" rid="article-23092.r74">[74]</xref>&#x000a0;</p>
        <p>
<bold>Primary Versus Secondary Hyperaldosteronism</bold>
</p>
        <p>Serum renin levels are the most effective way to differentiate between primary and secondary hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r37">[37]</xref> Primary hyperaldosteronism always significantly suppresses renal renin production, whereas secondary hyperaldosteronism is associated with elevated serum renin concentrations.<xref ref-type="bibr" rid="article-23092.r35">[35]</xref> Secondary hyperaldosteronism tends to have higher aldosterone levels and blood pressure.&#x000a0;</p>
        <p>
<bold>Hyperaldosteronism Confirmation</bold>
</p>
        <p>Confirmation of primary hyperaldosteronism<bold>&#x000a0;</bold>may not be necessary in selected cases that demonstrate the&#x000a0;combination of a markedly elevated plasma aldosterone, suppressed serum renin, hypokalemia, and resistant hypertension, although localization studies would still be needed.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref><xref ref-type="bibr" rid="article-23092.r75">[75]</xref><xref ref-type="bibr" rid="article-23092.r76">[76]</xref>&#x000a0;</p>
        <p>Confirmatory testing for hyperaldosteronism typically includes measuring an elevated serum aldosterone level, conducting a 24-hour urinary aldosterone excretion test, or performing an aldosterone suppression test using salt-loading, captopril, or fludrocortisone, which would typically be expected to cause aldosterone suppression.&#x000a0;All of these tests, except the captopril suppression test, may increase hypertension, induce fluid overload, and produce hypokalemia.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref>&#x000a0;No specific confirmatory test is officially preferred; however, a comparative meta-analysis suggested that the captopril challenge test may be the most feasible as it is easy to perform and considered relatively safe.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref><xref ref-type="bibr" rid="article-23092.r77">[77]</xref></p>
        <p>Before performing confirmatory testing, any existing hypokalemia should be corrected.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref>&#x000a0;Negative or equivocal results from confirmatory testing in patients with positive blood screening of an aldosterone-to-renin ratio of more than 20 with low serum renin likely have mild hyperaldosteronism. They are typically treated medically with mineralocorticoid receptor antagonists (eg, spironolactone).<xref ref-type="bibr" rid="article-23092.r47">[47]</xref>&#x000a0;Each of these confirmatory tests is conducted using the following methods:</p>
        <p>
<bold>Oral salt-loading test</bold>
</p>
        <p>This test usually involves significant dietary sodium loading and subsequent measurement of aldosterone levels. The oral salt-loading test consists of oral sodium loading over 3 days, usually 5000 to 6000 mg of dietary sodium daily or 90 mEq sodium tablets. Potassium supplements are provided to those who develop hypokalemia. After the sodium loading, a 24-hour urine aldosterone measurement is taken, with a value of &#x0003e;12 mcg/d commonly used to confirm primary hyperaldosteronism. A 24-hour urine sodium test of more than or equal to 200 mEq indicates adequate oral salt intake.</p>
        <p>Some considerations with this test include that renal failure can complicate result interpretation by producing false negatives. Additionally, the test should not be administered to patients with a history of congestive heart failure, uncontrolled significant hypertension, or cardiac arrhythmias.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref></p>
        <p>
<bold>Intravenous salt-loading test</bold>
</p>
        <p>This test is performed by administering 2 L of isotonic saline intravenously over 4 hours. Plasma aldosterone levels greater than 10 ng/dL following the infusion are consistent with primary hyperaldosteronism; however, the saline infusion has a false-negative rate of 30%.<xref ref-type="bibr" rid="article-23092.r27">[27]</xref>&#x000a0;A modified version of the saline infusion test, which includes 0.5 mg of oral dexamethasone every 6 hours for 2 days, has demonstrated greater sensitivity.<xref ref-type="bibr" rid="article-23092.r78">[78]</xref>&#x000a0;Drawbacks of this test include the need for hospitalization and potential risks such as fluid overload, worsening heart failure, hypokalemia, and increased blood pressure.</p>
        <p>
<bold>Captopril suppression test</bold>
</p>
        <p>The results of this test confirm primary hyperaldosteronism by evaluating the response to captopril&#x02014;an angiotensin II blocker.&#x000a0;In patients with primary hyperaldosteronism, aldosterone production remains elevated, while it should decrease in all other conditions. Patients are administered 25 to 50 mg of captopril, and serum aldosterone, renin, and cortisol levels are measured before and 1 to 2 hours after captopril administration.</p>
        <p>In primary hyperaldosteronism, aldosterone is expected to decrease by at least 30%, resulting in an aldosterone-to-renin ratio of less than 30:1. However, serum aldosterone levels will typically remain elevated (&#x02265;8.5 ng/dL) with an aldosterone-to-renin ratio greater than 30:1 and low renin levels. The captopril suppression test is relatively safe, quick to perform as an outpatient, and inexpensive. Despite this, it has a relatively high rate of equivocal and false-negative results. Additionally, it is not recommended for suspected renovascular hypertension and may cause angioedema.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref></p>
        <p>
<bold>Fludrocortisone suppression test</bold>
</p>
        <p>This&#x000a0;test aims to lower aldosterone levels by administering oral fludrocortisone, potassium supplementation, and salt loading. If aldosterone levels are not adequately suppressed after 4 days of treatment, it is considered confirmatory for primary hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r79">[79]</xref><xref ref-type="bibr" rid="article-23092.r80">[80]</xref>&#x000a0;Patients receive 0.1 mg of oral fludrocortisone every 6 hours, with potassium and sodium chloride tablets taken 3 times daily with meals and a high sodium diet.</p>
        <p>Aldosterone and renin levels are measured after 4 days. A serum aldosterone level of more than 6 ng/dL is considered a positive test and indicative of primary hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r79">[79]</xref><xref ref-type="bibr" rid="article-23092.r80">[80]</xref>&#x000a0;However, this test is labor-intensive and relatively costly.&#x000a0;Adding a 2 mg dose of dexamethasone at midnight can enhance the reliability, sensitivity, and specificity of the fludrocortisone suppression test, improving its ability to detect milder forms of primary hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r81">[81]</xref><xref ref-type="bibr" rid="article-23092.r82">[82]</xref><xref ref-type="bibr" rid="article-23092.r83">[83]</xref><xref ref-type="bibr" rid="article-23092.r84">[84]</xref><xref ref-type="bibr" rid="article-23092.r85">[85]</xref><xref ref-type="bibr" rid="article-23092.r86">[86]</xref>&#x000a0;</p>
        <p>Negative or equivocal results from confirmatory testing in patients with positive blood screenings showing an aldosterone-to-renin ratio &#x0003e;20 with low serum renin suggest probable mild hyperaldosteronism. Such cases are generally treated medically with mineralocorticoid receptor antagonists, such as spironolactone.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref></p>
        <p>
<bold>Differentiating Unilateral From Bilateral Disease</bold>
</p>
        <p>Determining laterality is essential as it directly affects treatment and outcomes. Differentiating between adenoma and adrenal hyperplasia also aids in establishing laterality. The following findings may be helpful:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum&#x000a0;18-hydroxycorticosterone levels are elevated in adenomas but normal in bilateral adrenal hyperplasia. Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19895">Conn Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>An adrenal adenoma shows a paradoxical decrease in serum aldosterone levels after&#x000a0;2 hours of upright positioning, whereas adrenal hyperplasia usually shows a normal or expected increase.&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19895">Conn Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Adrenal adenomas that autonomously overproduce aldosterone tend to be glucocorticoid-responsive, while bilateral idiopathic adrenal hyperplasia is generally not, although it may still respond somewhat to serum renin levels.<xref ref-type="bibr" rid="article-23092.r87">[87]</xref></p>
          </list-item>
        </list>
        <p>None of these findings are considered definitive to demonstrate laterality, which would require imaging studies or the more challenging but definitive adrenal vein sampling procedure.</p>
        <p>
<bold>Diagnostic studies</bold>
</p>
        <p>Radiological imaging, such as a CT scan, can distinguish adenomas from bilateral adrenal hyperplasia. However, studies have found that CT imaging alone cannot always reliably distinguish between them.<xref ref-type="bibr" rid="article-23092.r88">[88]</xref>&#x000a0;The overall sensitivity and specificity of CT imaging for aldosterone-producing adenomas are about 78% and 75%, respectively.</p>
        <p>All patients with primary aldosteronism should undergo imaging to rule out large adrenal masses or carcinomas.<xref ref-type="bibr" rid="article-23092.r27">[27]</xref> Aldosterone-producing adrenal tumors tend to be homogenous and lipid-rich with low Hounsfield density numbers, but imaging alone cannot reliably distinguish between functioning and nonfunctioning adrenal adenomas.<xref ref-type="bibr" rid="article-23092.r89">[89]</xref><xref ref-type="bibr" rid="article-23092.r90">[90]</xref><xref ref-type="bibr" rid="article-23092.r91">[91]</xref>&#x000a0;However, nonfunctional adrenal adenomas are extremely rare in children and young adults.<xref ref-type="bibr" rid="article-23092.r27">[27]</xref></p>
        <p>Adrenal vein sampling is used to differentiate unilateral from bilateral pathology if radiological imaging is not helpful and the patient is potentially a candidate for adrenal surgery.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref> Cortisol and aldosterone are measured in the right and left adrenal veins (LAVs); cortisol is used to verify catheter placement. Bilateral hyperplasia will demonstrate similar values on either side. However, a significant variance in the aldosterone concentration, at least double, or an aldosterone-to-cortisol ratio of at least 5-fold between the 2 sides suggests unilateral disease.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref><xref ref-type="bibr" rid="article-23092.r27">[27]</xref><xref ref-type="bibr" rid="article-23092.r92">[92]</xref><xref ref-type="bibr" rid="article-23092.r93">[93]</xref>&#x000a0;When optional cosyntropin stimulation is administered, a 4-fold difference in adrenal vein aldosterone levels is used as the cutoff threshold.<xref ref-type="bibr" rid="article-23092.r27">[27]</xref><xref ref-type="bibr" rid="article-23092.r92">[92]</xref><xref ref-type="bibr" rid="article-23092.r93">[93]</xref></p>
        <p>Adrenal vein sampling is not recommended in patients aged 35 and younger with spontaneous hypokalemia, marked levels of aldosterone, and highly suspicious adrenal adenomas on CT imaging. Nonfunctioning adrenal adenomas are rare in such younger populations. However, adrenal vein sampling is not required even in patients aged 40 or older with marked hyperaldosteronism with a clear solitary, unilateral adrenal adenoma on CT, those who are not surgical candidates, those suspected of adrenal cancer, and those with known familial hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r94">[94]</xref>&#x000a0;</p>
        <p>Adrenal vein sampling is still considered the gold standard for differentiating unilateral from bilateral adrenal hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref> However, the test is complex and technically demanding, as the vessels are relatively small;&#x000a0;therefore, the interpretation can be challenging.<xref ref-type="bibr" rid="article-23092.r92">[92]</xref>&#x000a0;The right adrenal vein, in particular, can be exceedingly challenging to cannulate.&#x000a0;Even unilateral adrenal vein sampling can be helpful.</p>
        <p>In 2016, Pasternak&#x000a0;et al suggested the following method for cases&#x000a0;where only unilateral adrenal vein sampling was accomplished:</p>
        <list list-type="bullet">
          <list-item>
            <p>The formula, (adrenal vein aldosterone&#x000a0;<italic toggle="yes">&#x000f7;</italic>&#x000a0;cortisol) / (inferior vena cava [IVC]&#x000a0;aldosterone&#x000a0;<italic toggle="yes">&#x000f7; </italic>IVC<italic toggle="yes">&#x000a0;</italic>cortisol), is used to calculate the LAV/IVC ratio cutoff value&#x000a0;<xref ref-type="bibr" rid="article-23092.r95">[95]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Values greater than 5.5 indicate unilateral hyperaldosteronism on the side tested, while results less than 0.5 predict the same but on the contralateral side.<xref ref-type="bibr" rid="article-23092.r95">[95]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Values between 5.5 and 0.5 are not interpretable and may indicate either bilateral or unilateral disease.<xref ref-type="bibr" rid="article-23092.r95">[95]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>This method has an estimated specificity of 100% but only 50% sensitivity; other studies have confirmed these findings.<xref ref-type="bibr" rid="article-23092.r95">[95]</xref><xref ref-type="bibr" rid="article-23092.r96">[96]</xref><xref ref-type="bibr" rid="article-23092.r97">[97]</xref></p>
        <p>Adrenal venous sampling carries risks, including adrenal venous rupture, infarction, thrombus formation, bleeding, and hematoma formation.&#x000a0;Therefore, the procedure should ideally be performed in centers of excellence with experience and expertise in this procedure.&#x000a0;For these reasons, various noninvasive alternative diagnostic modalities to adrenal venous sampling are being explored. These tend to be cumbersome to perform with somewhat limited accuracy but may be helpful where there is experience and availability.</p>
        <p><bold>Alternative diagnostic modalities:&#x000a0;</bold>Alternative diagnostic modalities for determining laterality in hyperaldosteronism include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Scintigraphy with NP-59&#x000a0;(131 I-6-&#x003b2;-iodomethyl-19-norcholesterol) with dexamethasone suppression can be used in selected cases to help differentiate between unilateral functioning adenomas and bilateral hyperplasia, especially if adrenal vein sampling is unsuccessful or cannot be performed and the patient would otherwise be a candidate for surgical intervention.<xref ref-type="bibr" rid="article-23092.r98">[98]</xref><xref ref-type="bibr" rid="article-23092.r99">[99]</xref><xref ref-type="bibr" rid="article-23092.r100">[100]</xref>&#x000a0;This modality can also identify laterality in primary hyperaldosteronism&#x000a0;and may be beneficial in patients with chronic kidney disease where standard biochemical testing is more problematic.<xref ref-type="bibr" rid="article-23092.r99">[99]</xref><xref ref-type="bibr" rid="article-23092.r100">[100]</xref>&#x000a0;The positive predictive value and sensitivity in this modality have been reported as about 92%.<xref ref-type="bibr" rid="article-23092.r99">[99]</xref> However, it is a difficult test and may not be available in many centers.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The <sup>11</sup>C-metomidate positron emission tomography (PET)-CT scanning modality with and without dexamethasone suppression is a sensitive and specific test for primary hyperaldosteronism and adrenocortical tumors.<xref ref-type="bibr" rid="article-23092.r101">[101]</xref><xref ref-type="bibr" rid="article-23092.r102">[102]</xref><xref ref-type="bibr" rid="article-23092.r103">[103]</xref><xref ref-type="bibr" rid="article-23092.r104">[104]</xref><xref ref-type="bibr" rid="article-23092.r105">[105]</xref><xref ref-type="bibr" rid="article-23092.r106">[106]</xref>&#x000a0;In addition, this scan may reliably predict the response to medical therapy for hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r104">[104]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gallium-68 pentixafor PET-CT scanning has demonstrated a correlation in differentiating between unilateral and bilateral hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r107">[107]</xref> In a study, the gallium-68 PET-CT scan showed a 90% correlation with adrenal vein sampling compared to only 54% with CT scans.<xref ref-type="bibr" rid="article-23092.r107">[107]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Genetic Testing</bold>
</p>
        <p>Genetic testing is recommended for patients with primary aldosteronism who are aged 20 or younger or have a family history of the disorder. Familial hyperaldosteronism accounts for approximately 6% to 7% of all adult cases of primary hyperaldosteronism. Notably, 4 types of familial hyperaldosteronism have been described, with type I (glucocorticoid-responsive hyperaldosteronism) and type III (glucocorticoid-unresponsive hyperaldosteronism) being the most common.<xref ref-type="bibr" rid="article-23092.r27">[27]</xref>&#x000a0;In severe cases, bilateral adrenalectomies may be necessary to manage blood pressure and severe hypokalemia, which requires lifelong glucocorticoid and mineralocorticoid replacement therapy.</p>
        <p>
<bold>Hyperaldosteronism Evaluation Summary</bold>
</p>
        <p>The initial step in evaluating hyperaldosteronism is to differentiate between primary and secondary hyperaldosteronism. This is relatively straightforward, as primary hyperaldosteronism is characterized by a high aldosterone-to-renin ratio (&#x0003e;20:1) and low serum renin levels. A confirmatory test is typically recommended but may be omitted in selected cases.<xref ref-type="bibr" rid="article-23092.r20">[20]</xref><xref ref-type="bibr" rid="article-23092.r26">[26]</xref><xref ref-type="bibr" rid="article-23092.r75">[75]</xref><xref ref-type="bibr" rid="article-23092.r76">[76]</xref></p>
        <p>If primary hyperaldosteronism is diagnosed, the next step is to differentiate between unilateral disease, which is treated surgically, and bilateral disease, which is managed with medical therapy.<xref ref-type="bibr" rid="article-23092.r108">[108]</xref><xref ref-type="bibr" rid="article-23092.r109">[109]</xref><xref ref-type="bibr" rid="article-23092.r110">[110]</xref><xref ref-type="bibr" rid="article-23092.r111">[111]</xref> Unilateral disease is traditionally confirmed with bilateral selective adrenal venous sampling, although CT scans and other imaging modalities may also be utilized.<xref ref-type="bibr" rid="article-23092.r27">[27]</xref><xref ref-type="bibr" rid="article-23092.r92">[92]</xref>&#x000a0;Secondary hyperaldosteronism, characterized by elevated serum renin levels, is best treated by eliminating the underlying etiology and using appropriate medical therapy.</p>
      </sec>
      <sec id="article-23092.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Unilateral&#x000a0;Primary Hyperaldosteronism Management</bold>
</p>
        <p>Primary hyperaldosteronism caused by unilateral disease is best treated surgically. Robotic or laparoscopic adrenalectomy is preferred as these procedures are associated with fewer complications and a shorter hospital stay compared to open surgery.<xref ref-type="bibr" rid="article-23092.r89">[89]</xref>&#x000a0;Complete&#x000a0;adrenalectomy is preferred to partial gland removal due to greater efficacy and resolution of symptoms. Primary hyperaldosteronism is the most frequently encountered surgically curable etiology of hypertension.<xref ref-type="bibr" rid="article-23092.r112">[112]</xref>&#x000a0;</p>
        <p>Preoperative spironolactone to control blood pressure for 4 to 6 weeks is recommended.&#x000a0;Patients who fail to normalize their blood pressure on spironolactone preoperatively are likely to continue to be hypertensive even after surgery.&#x000a0;Following surgery, about two-thirds of patients will eventually develop stable, normal blood pressure, although this may take a year. Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19895">Conn Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r8">[8]</xref></p>
        <p>Patients with hyperaldosteronism due to unilateral disease fare better long-term with surgery than with medical therapy regarding blood pressure control, maintaining serum potassium levels, and improved vascular remodeling.<xref ref-type="bibr" rid="article-23092.r113">[113]</xref>&#x000a0;Failure of surgery to control hypertension despite the normalization of aldosterone levels suggests the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>An&#x000a0;erroneous or inadequate initial diagnosis of unilateral hyperaldosteronism&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Underlying essential hypertension</p>
          </list-item>
          <list-item>
            <p>Vascular abnormalities or damage from chronic hyperaldosteronism</p>
          </list-item>
          <list-item>
            <p>Other unrelated causes of hypertension (eg, pheochromocytoma or renovascular disease)</p>
          </list-item>
        </list>
        <p>Good outcomes from surgery without adequate localization occur in less than 20% of patients.<xref ref-type="bibr" rid="article-23092.r114">[114]</xref>&#x000a0;The medical therapy of choice for nonsurgical candidates is mineralocorticoid receptor antagonists, such as spironolactone and eplerenone.<xref ref-type="bibr" rid="article-23092.r115">[115]</xref><xref ref-type="bibr" rid="article-23092.r116">[116]</xref><xref ref-type="bibr" rid="article-23092.r117">[117]</xref> Please see the companion StatPearls' reference resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/29371">Spironolactone</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/21264">Eplerenone</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r118">[118]</xref><xref ref-type="bibr" rid="article-23092.r119">[119]</xref>&#x000a0;Amiloride, a potassium-sparing diuretic, may also be used.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref></p>
        <p>Transcatheter and percutaneous adrenal ablation appear to be acceptable, less invasive surgical therapies for primary unilateral hyperaldosteronism, with a clinical success rate reported at about 75%.<xref ref-type="bibr" rid="article-23092.r120">[120]</xref><xref ref-type="bibr" rid="article-23092.r121">[121]</xref><xref ref-type="bibr" rid="article-23092.r122">[122]</xref><xref ref-type="bibr" rid="article-23092.r123">[123]</xref><xref ref-type="bibr" rid="article-23092.r124">[124]</xref><xref ref-type="bibr" rid="article-23092.r125">[125]</xref>&#x000a0;These procedures are currently recommended for suitable patients unwilling to have surgery or take long-term medications.<xref ref-type="bibr" rid="article-23092.r120">[120]</xref><xref ref-type="bibr" rid="article-23092.r121">[121]</xref><xref ref-type="bibr" rid="article-23092.r122">[122]</xref><xref ref-type="bibr" rid="article-23092.r123">[123]</xref><xref ref-type="bibr" rid="article-23092.r124">[124]</xref><xref ref-type="bibr" rid="article-23092.r125">[125]</xref>&#x000a0;Partial adrenalectomy may be possible in some patients as it provides similar outcomes with fewer postoperative complications, but it carries a potential risk of leaving part of the abnormal aldosterone-secreting tissue behind.<xref ref-type="bibr" rid="article-23092.r126">[126]</xref>&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/32644519">Adrenalectomy</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r127">[127]</xref></p>
        <p>
<bold>Treatment of Primary Hyperaldosteronism Secondary to Bilateral Hyperplasia</bold>
</p>
        <p>Mineralocorticoid receptor antagonists are the treatments of choice for primary hyperaldosteronism caused by bilateral hyperplasia and for patients who are not surgical candidates. Spironolactone or eplerenone are most commonly used. The selection of these agents depends on the adverse effect profile, physician experience, and individual patient characteristics.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Spironolactone&#x000a0;</bold>is usually the preferred medical therapy, starting at 12.5 to 25 mg daily and titrated upward every 2 weeks according to the 2016 Endocrine Society Guidelines.<xref ref-type="bibr" rid="article-23092.r117">[117]</xref>&#x000a0;Maintenance is often reached at a daily dosage of about 100 mg of spironolactone. Gynecomastia is a significant known adverse effect of spironolactone use in men, which may occur in up to 50% of male patients who take more than 150 mg daily. Please see the StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/29371">Spironolactone</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r118">[118]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Eplerenone</bold>&#x000a0;is a more specific medication that, unlike spironolactone, does not block androgen receptors.&#x000a0;This makes it more acceptable and preferred for long-term treatment in men as it avoids possible gynecomastia and erectile dysfunction, especially if low-dose spironolactone is not effective.&#x000a0;Eplerenone has a relatively short half-life of about 4 hours, which is longer than spironolactone's half-life of only 1.4 hours.&#x000a0;However, spironolactone is more effective in controlling blood pressure.<xref ref-type="bibr" rid="article-23092.r128">[128]</xref>&#x000a0;Eplerenone is usually started at 50 mg daily and titrated upward, up to a maximum of about 200 mg twice a day.&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/21264">Eplerenone</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r119">[119]</xref></p>
          </list-item>
        </list>
        <p>Patients with bilateral or idiopathic hyperaldosteronism are typically treated medically with either spironolactone or eplerenone for blood pressure control but still tend to have higher rates of cardiovascular events than other hypertensive patients, as higher&#x000a0;levels of serum aldosterone correspond to a greater cardiovascular risk.<xref ref-type="bibr" rid="article-23092.r129">[129]</xref>&#x000a0;This has led to investigations into alternative therapies where standard surgery could not be utilized.</p>
        <p>The feasibility of bilateral superselective adrenal artery embolization for treating idiopathic primary hyperaldosteronism has been demonstrated.<xref ref-type="bibr" rid="article-23092.r130">[130]</xref><xref ref-type="bibr" rid="article-23092.r131">[131]</xref><xref ref-type="bibr" rid="article-23092.r132">[132]</xref><xref ref-type="bibr" rid="article-23092.r133">[133]</xref><xref ref-type="bibr" rid="article-23092.r134">[134]</xref><xref ref-type="bibr" rid="article-23092.r135">[135]</xref>&#x000a0;Early studies indicate that such selective embolization therapy produces long-term, sustained improvement in serum aldosterone levels, aldosterone: renin ratios, hypokalemia, and blood pressure with no significant side effects or adverse events after 1 year of follow-up.<xref ref-type="bibr" rid="article-23092.r130">[130]</xref><xref ref-type="bibr" rid="article-23092.r131">[131]</xref><xref ref-type="bibr" rid="article-23092.r132">[132]</xref><xref ref-type="bibr" rid="article-23092.r133">[133]</xref><xref ref-type="bibr" rid="article-23092.r134">[134]</xref><xref ref-type="bibr" rid="article-23092.r135">[135]</xref>&#x000a0;This suggests that bilateral superselective adrenal artery embolization could represent a reasonable and effective alternative therapy for idiopathic primary hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r130">[130]</xref><xref ref-type="bibr" rid="article-23092.r131">[131]</xref><xref ref-type="bibr" rid="article-23092.r132">[132]</xref><xref ref-type="bibr" rid="article-23092.r133">[133]</xref><xref ref-type="bibr" rid="article-23092.r134">[134]</xref><xref ref-type="bibr" rid="article-23092.r135">[135]</xref></p>
        <p>
<bold>Other Potassium-Sparing Diuretics</bold>
</p>
        <p>The clinical course ultimately dictates the drug selection, dosage, and frequency. Reports of spontaneous remission of primary hyperaldosteronism after long-term therapy with mineralocorticoid receptor antagonist medications are rare.<xref ref-type="bibr" rid="article-23092.r136">[136]</xref>&#x000a0;Triamterene and amiloride are potassium-sparing diuretics that may have an adjunctive role in managing aldosterone-related hypertension. However, amiloride is preferred as triamterene may form urinary calculi.<xref ref-type="bibr" rid="article-23092.r137">[137]</xref><xref ref-type="bibr" rid="article-23092.r138">[138]</xref><xref ref-type="bibr" rid="article-23092.r139">[139]</xref><xref ref-type="bibr" rid="article-23092.r140">[140]</xref>&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/30575">Triamterene</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r141">[141]</xref></p>
        <p>Canrenone is an active metabolite of spironolactone with similar activity but a much longer half-life (16.5 hours versus 1.4 hours) and fewer sexual adverse&#x000a0;effects.<xref ref-type="bibr" rid="article-23092.r142">[142]</xref>&#x000a0;Canrenone appears to have a direct beneficial myocardial effect beyond its antihypertensive actions. Although currently available in Europe, canrenone is not yet available in the United States. Medications specifically targeting aldosterone-producing adrenal CYP-11B2 cells are being developed and investigated, though this is complex due to the close similarity between CYP-11B2 and CYP-11B1 cells.<xref ref-type="bibr" rid="article-23092.r143">[143]</xref><xref ref-type="bibr" rid="article-23092.r144">[144]</xref><xref ref-type="bibr" rid="article-23092.r145">[145]</xref></p>
        <p>
<bold>Combination therapy</bold>
</p>
        <p>Combination therapy, including medications, sodium restriction (usually &#x0003c;100 mEq/d), avoidance of alcohol, smoking cessation, aerobic exercise, and maintaining ideal body weight, generally yields the best results.<xref ref-type="bibr" rid="article-23092.r117">[117]</xref><xref ref-type="bibr" rid="article-23092.r146">[146]</xref><xref ref-type="bibr" rid="article-23092.r147">[147]</xref> Additional treatments, such as glucocorticoids, amiloride, and calcium channel blockers, may be used to manage hypertension and other symptoms not adequately controlled by mineralocorticoid receptor antagonists alone.<xref ref-type="bibr" rid="article-23092.r47">[47]</xref> In rare cases, surgery involving bilateral adrenalectomies may be considered for patients with hyperaldosteronism secondary to bilateral adrenal hyperplasia who are refractory to maximum medical treatment.<xref ref-type="bibr" rid="article-23092.r148">[148]</xref></p>
        <p>
<bold>Secondary Hyperaldosteronism Management</bold>
</p>
        <p>Secondary hyperaldosteronism is best managed by addressing the underlying disease, which typically resolves the symptoms. ACE inhibitors (ACE I) and angiotensin receptor blockers are preferred for blood pressure control in these patients due to their renal protective benefits. In addition, salt restriction is recommended for better control of blood pressure.<xref ref-type="bibr" rid="article-23092.r149">[149]</xref>&#x000a0;Please see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/29371">Spironolactone</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r118">[118]</xref></p>
        <p>Potassium supplements and potassium-sparing diuretics may also be used to manage secondary hyperaldosteronism. The treatment approach is similar to that for primary hyperaldosteronism caused by idiopathic adrenal hyperplasia. In cases of renal artery stenosis, surgical intervention or revascularization may be necessary to achieve optimal blood pressure control.&#x000a0;Please see the companion StatPearls' reference resource,&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/28335">Renal Artery Stenosis</ext-link>," for additional information.<xref ref-type="bibr" rid="article-23092.r39">[39]</xref></p>
      </sec>
      <sec id="article-23092.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Presentations similar to hyperaldosteronism can be observed in various conditions, including&#x000a0;essential hypertension, Liddle syndrome, syndrome of apparent mineralocorticoid excess, congenital adrenal hyperplasia, primary glucocorticoid resistance, Cushing syndrome (hypercortisolism), aldosterone-producing renin-responsive adenomas, adrenocortical carcinomas, metabolic alkalosis, diabetes insipidus, preeclampsia, Gitelman syndrome, renal artery stenosis, Bartter syndrome, pheochromocytoma, Chr&#x000e9;tien syndrome, excessive licorice intake, and ectopic ACTH syndrome.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref> Please see StatPearls' companion resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/18152">Bartter Syndrome</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22254">Gitelman Syndrome</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r16">[16]</xref><xref ref-type="bibr" rid="article-23092.r41">[41]</xref></p>
        <p>The following presentations are some of the shared clinical features:</p>
        <list list-type="bullet">
          <list-item>
            <p>17-Alpha-hydroxylase deficiency: This condition can closely mimic hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r150">[150]</xref>&#x000a0;Patients typically present with hypogonadism and immature genitalia.<xref ref-type="bibr" rid="article-23092.r150">[150]</xref>&#x000a0;Genetic testing may be required for a definitive diagnosis.<xref ref-type="bibr" rid="article-23092.r150">[150]</xref>&#x000a0;Please see the companion StatPearls' reference resource,&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/31536251">17-Hydroxylase Deficiency</ext-link>," for additional information.<xref ref-type="bibr" rid="article-23092.r151">[151]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chr&#x000e9;tien syndrome: This&#x000a0;syndrome is a rare disorder caused by excess secretion of proopiomelanocortin, a precursor of ACTH, from a pituitary adenoma. This results in adrenocortical hypertension.<xref ref-type="bibr" rid="article-23092.r152">[152]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Congenital adrenal hyperplasia: This condition is typically associated&#x000a0;with a family history of 11-beta-hydroxylase or 17-alpha-hydroxylase deficiency and is characterized by low aldosterone levels.&#x000a0;Please see the companion StatPearls' reference resources,&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28846271">Congenital Adrenal Hyperplasia</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/31536251">17-Hydroxylase Deficiency</ext-link>," for additional information.<xref ref-type="bibr" rid="article-23092.r151">[151]</xref><xref ref-type="bibr" rid="article-23092.r153">[153]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ectopic&#x000a0;ACTH syndrome: This condition is characterized by elevated ACTH levels that cannot be suppressed with high-dose dexamethasone. These patients often have an underlying tumor.<xref ref-type="bibr" rid="article-23092.r154">[154]</xref><xref ref-type="bibr" rid="article-23092.r155">[155]</xref><xref ref-type="bibr" rid="article-23092.r156">[156]</xref><xref ref-type="bibr" rid="article-23092.r157">[157]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Essential hypertension: This condition typically presents with a normal PAC/PRA ratio.&#x000a0;Please see the companion StatPearls' reference resource,&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/30725596">Essential Hypertension</ext-link>," for additional information.<xref ref-type="bibr" rid="article-23092.r158">[158]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Excessive licorice intake: This condition inhibits the renal conversion of cortisol to cortisone, producing a cortisol excess, which acts as a mineralocorticoid agonist simulating hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r159">[159]</xref><xref ref-type="bibr" rid="article-23092.r160">[160]</xref><xref ref-type="bibr" rid="article-23092.r159">[159]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Liddle syndrome: This syndrome is a rare genetic disorder that presents with low aldosterone levels and typically manifests in childhood.&#x000a0;Symptoms include hypertension, hypokalemia, and metabolic alkalosis, which are similar to mineralocorticoid excess disorders. Liddle syndrome is often referred to as pseudohyperaldosteronism, which is characterized by high urinary potassium secretion and sodium reabsorption in the renal collecting tubules despite low aldosterone levels.&#x000a0;Please see the companion StatPearls' reference resource,&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/30725596">Liddle Syndrome (Pseudohyperaldosteronism)</ext-link>," for additional information.<xref ref-type="bibr" rid="article-23092.r161">[161]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Primary glucocorticoid resistance: This condition&#x000a0;features low aldosterone levels, elevated ACTH and cortisol, and often has a family history of the syndrome.<xref ref-type="bibr" rid="article-23092.r162">[162]</xref><xref ref-type="bibr" rid="article-23092.r163">[163]</xref><xref ref-type="bibr" rid="article-23092.r164">[164]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Syndrome of apparent mineralocorticoid excess: This syndrome presents with hypertension, low aldosterone levels, high urinary free cortisol levels, hypokalemia, ACTH suppression, hereditary implications, and a history of excessive licorice consumption.<xref ref-type="bibr" rid="article-23092.r165">[165]</xref>&#x000a0;Genetically, it is an autosomal recessive disorder.<xref ref-type="bibr" rid="article-23092.r165">[165]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hyperaldosteronism and Hypercortisolism</bold>
</p>
        <p>Hyperaldosteronism and hypercortisolism (ie, Cushing syndrome and disease)&#x000a0;share several clinical and laboratory features due to their involvement with abnormal adrenal function. Both conditions are 3 times more common in women than in men, are most frequently diagnosed in patients aged 25 to 50, and typically present with hypertension, hypokalemia, and hypernatremia.</p>
        <p>In hyperaldosteronism, patients typically present with intractable hypertension resistant to standard drug therapies.<xref ref-type="bibr" rid="article-23092.r27">[27]</xref>&#x000a0;Hyperaldosteronism is a relatively common disorder, affecting approximately 10% of all hypertensive individuals, with over 20% experiencing resistant hypertension.<xref ref-type="bibr" rid="article-23092.r24">[24]</xref><xref ref-type="bibr" rid="article-23092.r166">[166]</xref>&#x000a0;Therefore, hyperaldosteronism should be considered in any patient with hypertension that is difficult to control. Diagnosis often begins with a blood test showing a high aldosterone-to-renin ratio and low plasma renin levels, as previously described.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/23092#link_37964158">[23]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/23092#link_3881606">[35]</ext-link> Please&#x000a0;see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/23093">Primary Hyperaldosteronism</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref></p>
        <p>Conversely, patients with hypercortisolism often exhibit less severe hypertension. Hypercortisolism is rare, occurring at an estimated rate of 60 cases per million individuals.<xref ref-type="bibr" rid="article-23092.r167">[167]</xref>&#x000a0;Hypercortisolism is initially suspected based on clinical features such as weight gain, muscle weakness, thin extremities, a rounded face, a fat pad at the base of the neck, easy bruising, thin skin, acne, hirsutism, and purplish stretch marks. A&#x000a0;24-hour urine test for free cortisol is typically used for the initial diagnosis, while a dexamethasone suppression test serves as a confirmatory measure.&#x000a0;Please see the companion StatPearls' reference resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/31194457">Dexamethasone Suppression Test</ext-link>," "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/20178">Cushing Syndrome</ext-link>," and&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/31855370">Hypercortisolism</ext-link>," for additional information.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="31855370">[146]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="29261900">[161]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="31855370">[163]</ext-link></p>
      </sec>
      <sec id="article-23092.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Few studies have examined mortality rates for either form of hyperaldosteronism, but results suggest that the reported 10-year survival rates for treated patients range from 90% to 95%. The most common morbidity associated with hyperaldosteronism is cardiovascular-related, although overall mortality rates do not significantly differ from those of the general population.&#x000a0;</p>
        <p>If hypokalemia persists, it can lead to symptoms such as weakness, paralysis, constipation, and polyuria. Additionally, primary hyperaldosteronism and hypokalemia can impair insulin secretion, increasing the risk of developing diabetes mellitus.<xref ref-type="bibr" rid="article-23092.r33">[33]</xref><xref ref-type="bibr" rid="article-23092.r34">[34]</xref><xref ref-type="bibr" rid="article-23092.r35">[35]</xref>&#x000a0;About&#x000a0;two-thirds&#x000a0;of patients become normotensive after adrenal surgery, although this&#x000a0;improvement may take up to a year. By 5 years post-surgery, about half of these patients remain normotensive without medication. Untreated hyperaldosteronism is associated with significant morbidity and mortality, largely due to uncontrolled hypertension and cardiac arrhythmias.</p>
      </sec>
      <sec id="article-23092.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The most common complication and comorbidity associated with hyperaldosteronism is the increased risk of cardiovascular mortality due to excessive aldosterone secretion. Clinical manifestations can include atrial fibrillation, left ventricular hypertrophy, hypertension, myocardial infarction, and stroke.<xref ref-type="bibr" rid="article-23092.r168">[168]</xref><xref ref-type="bibr" rid="article-23092.r169">[169]</xref><xref ref-type="bibr" rid="article-23092.r170">[170]</xref><xref ref-type="bibr" rid="article-23092.r171">[171]</xref><xref ref-type="bibr" rid="article-23092.r172">[172]</xref>&#x000a0;In addition, myocardial fibrosis has been reported in patients with long-standing hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r173">[173]</xref><xref ref-type="bibr" rid="article-23092.r174">[174]</xref></p>
      </sec>
      <sec id="article-23092.s13" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Sodium restriction to less than 100 mEq/d, alcohol cessation, smoking cessation, maintaining an ideal body weight, and engaging in regular aerobic exercise are beneficial for postoperative care and overall health maintenance.</p>
      </sec>
      <sec id="article-23092.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Endocrinologists and nutritionists are generally well-equipped to manage this condition on a long-term basis. Surgical consultation is indicated for a subset of patients with unilateral primary hyperaldosteronism.</p>
      </sec>
      <sec id="article-23092.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be thoroughly informed and educated about their condition, emphasizing the importance of adhering to long-term treatment recommendations, including dietary modifications (eg, salt restriction) and full compliance with prescribed medications.</p>
      </sec>
      <sec id="article-23092.s16" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to bear in mind when managing hyperaldosteronism include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperaldosteronism testing should be routinely considered in all newly diagnosed patients with hypertension that is difficult to control with standard antihypertensives, especially if they are younger than 40, have hypokalemia, or have obstructive sleep apnea.<xref ref-type="bibr" rid="article-23092.r4">[4]</xref><xref ref-type="bibr" rid="article-23092.r27">[27]</xref><xref ref-type="bibr" rid="article-23092.r46">[46]</xref><xref ref-type="bibr" rid="article-23092.r175">[175]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A morning aldosterone-to-renin ratio is a reasonable initial screening test for hyperaldosteronism.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A PAC/PRA ratio&#x000a0;greater than 20:1, with a&#x000a0;PAC of more than&#x000a0;20 ng/dL, is highly suggestive of primary hyperaldosteronism, especially when associated with low renin and/or hypokalemia.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Serum renin levels are the most straightforward method for differentiating between primary and secondary hyperaldosteronism. In primary hyperaldosteronism, renin activity is typically suppressed, whereas it is elevated in secondary hyperaldosteronism. Additionally, blood pressure and aldosterone levels are generally higher in secondary hyperaldosteronism compared to primary hyperaldosteronism.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A 17&#x003b1;-hydroxylase deficiency can closely mimic primary or secondary hyperaldosteronism. Patients with this deficiency will often present with juvenile, undeveloped genitalia and hypogonadism.<xref ref-type="bibr" rid="article-23092.r150">[150]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Normal serum potassium in a patient with hypertension does not rule out hyperaldosteronism. Up to one-third or more of patients with primary hyperaldosteronism may have normal serum potassium levels at baseline.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A&#x000a0;significant overlap in aldosterone-to-renin ratios exists between primary hyperaldosteronism and essential resistant hypertension. However, if the patient has hypokalemia, an aldosterone-to-renin ratio is often sufficient to&#x000a0;diagnose hyperaldosteronism. Please&#x000a0;see the companion StatPearls' reference resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/23093">Primary Hyperaldosteronism</ext-link>," for more information.<xref ref-type="bibr" rid="article-23092.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypokalemia has traditionally been a key indicator of hyperaldosteronism but is present in fewer than 20% of cases.<xref ref-type="bibr" rid="article-23092.r176">[176]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypokalemia may be masked in patients on a salt-restricted diet.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with primary hyperaldosteronism due to functional adrenal adenomas are more likely to demonstrate hypokalemia.<xref ref-type="bibr" rid="article-23092.r177">[177]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyperaldosteronism is found in about 10% of all patients with high blood pressure but is present in over 20% of patients with medication-resistant hypertension.<xref ref-type="bibr" rid="article-23092.r20">[20]</xref><xref ref-type="bibr" rid="article-23092.r21">[21]</xref><xref ref-type="bibr" rid="article-23092.r22">[22]</xref><xref ref-type="bibr" rid="article-23092.r23">[23]</xref><xref ref-type="bibr" rid="article-23092.r24">[24]</xref><xref ref-type="bibr" rid="article-23092.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A patient's clinical history and presentation, family history, and response to prior treatment will guide which disorders should be tested for.<xref ref-type="bibr" rid="article-23092.r74">[74]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Genetic testing for familial hyperaldosteronism should be considered in patients with proven primary hyperaldosteronism who also have a suggestive family history.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Various computerized models utilizing machine learning, which integrate CT findings with clinical and biochemical data, are being developed to enhance the classification, subtyping, and lateralization of primary hyperaldosteronism.<xref ref-type="bibr" rid="article-23092.r178">[178]</xref><xref ref-type="bibr" rid="article-23092.r179">[179]</xref><xref ref-type="bibr" rid="article-23092.r180">[180]</xref><xref ref-type="bibr" rid="article-23092.r181">[181]</xref><xref ref-type="bibr" rid="article-23092.r182">[182]</xref><xref ref-type="bibr" rid="article-23092.r183">[183]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consider bilateral superselective adrenal artery embolization for patients with bilateral or idiopathic primary hyperaldosteronism. if available.<xref ref-type="bibr" rid="article-23092.r130">[130]</xref><xref ref-type="bibr" rid="article-23092.r131">[131]</xref><xref ref-type="bibr" rid="article-23092.r132">[132]</xref><xref ref-type="bibr" rid="article-23092.r133">[133]</xref><xref ref-type="bibr" rid="article-23092.r134">[134]</xref><xref ref-type="bibr" rid="article-23092.r135">[135]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23092.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diagnosing and managing hyperaldosteronism can be complex and is best handled by an interprofessional healthcare team, which includes a radiologist, pathologist, internist, endocrinologist, nurse practitioner, pharmacist, nurse, and surgeon. For primary hyperaldosteronism caused by unilateral disease, surgery is the preferred treatment. Robotic adrenalectomy is preferred due to its association with fewer complications and a shorter hospital stay compared to laparoscopy or open adrenal surgery. Complete adrenalectomy is preferred over partial adrenalectomy due to its greater efficacy and more complete resolution of symptoms.</p>
        <p>For nonsurgical candidates, mineralocorticoid receptor antagonists are the preferred medical therapy. In cases of bilateral hyperaldosteronism, medical treatment is recommended, and the initial drug of choice is spironolactone. However, eplerenone may be preferred for long-term management in men due to its lower risk of gynecomastia and sexual dysfunction. Pharmacists should support the clinical team by educating patients on the importance of long-term compliance with medical therapy. In addition, patients should also be informed about the risk of gynecomastia and sexual dysfunction with spironolactone, particularly at higher doses (&#x0003e;150 mg/d). Please see the StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/29371">Spironolactone</ext-link>," for more information.</p>
        <p>Primary care clinicians, nurses, and dietitians should educate patients and their families on the importance of salt restriction, alcohol cessation, smoking cessation, maintaining an ideal body weight, and regular aerobic exercise. Follow-up is essential due to the high risk of adverse cardiac events in these patients.&#x000a0;Only through an interprofessional team approach with close communication among members is crucial to reducing the morbidity associated with hyperaldosteronism.</p>
      </sec>
      <sec id="article-23092.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23092&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23092">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/hyperaldosteronism/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23092">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23092/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23092">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23092.s19">
        <title>References</title>
        <ref id="article-23092.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Scott</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Menouar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <chapter-title>Physiology, Aldosterone</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">29261963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cobb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <chapter-title>Primary Hyperaldosteronism</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">30969601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ananda</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gwini</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Delay and Disease Burden in Primary Aldosteronism: An International Patient Survey.</article-title>
            <source>Hypertension</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>348</fpage>
            <page-range>348-360</page-range>
            <pub-id pub-id-type="pmid">38095087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhandari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brettler</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kanter</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Hyperaldosteronism Screening and Findings From a Large Diverse Population With Resistant Hypertension Within an Integrated Health System.</article-title>
            <source>Perm J</source>
            <year>2024</year>
            <month>Mar</month>
            <day>15</day>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-13</page-range>
            <pub-id pub-id-type="pmid">38009955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funder</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine.</article-title>
            <source>Integr Blood Press Control</source>
            <year>2013</year>
            <month>Oct</month>
            <day>04</day>
            <volume>6</volume>
            <fpage>129</fpage>
            <page-range>129-38</page-range>
            <pub-id pub-id-type="pmid">24133375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Memon</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bandgar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Update on Primary Aldosteronism: Time to Screen All Hypertensives.</article-title>
            <source>J Assoc Physicians India</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-12</page-range>
            <pub-id pub-id-type="pmid">38736067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reznik</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>MANAGEMENT OF ENDOCRINE DISEASE: The role of confirmatory tests in the diagnosis of primary aldosteronism.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>180</volume>
            <issue>2</issue>
            <fpage>R45</fpage>
            <page-range>R45-R58</page-range>
            <pub-id pub-id-type="pmid">30475220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Parmar</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Conn Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">29083776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Elaraj</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and Management of Primary Hyperaldosteronism.</article-title>
            <source>Surg Clin North Am</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>99</volume>
            <issue>4</issue>
            <fpage>731</fpage>
            <page-range>731-745</page-range>
            <pub-id pub-id-type="pmid">31255203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funder</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The genetic basis of primary aldosteronism.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-4</page-range>
            <pub-id pub-id-type="pmid">22359160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halperin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dluhy</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Glucocorticoid-remediable aldosteronism.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>333</fpage>
            <page-range>333-41, viii</page-range>
            <pub-id pub-id-type="pmid">21565670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scholl</surname>
                <given-names>UI</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rklund</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nelson-Williams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Men</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lolis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wisgerhof</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Mane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hellman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Westin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>&#x000c5;kerstr&#x000f6;m</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Carling</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lifton</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension.</article-title>
            <source>Science</source>
            <year>2011</year>
            <month>Feb</month>
            <day>11</day>
            <volume>331</volume>
            <issue>6018</issue>
            <fpage>768</fpage>
            <page-range>768-72</page-range>
            <pub-id pub-id-type="pmid">21311022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quack</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vonend</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rump</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Familial hyperaldosteronism I-III.</article-title>
            <source>Horm Metab Res</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>424</fpage>
            <page-range>424-8</page-range>
            <pub-id pub-id-type="pmid">20131203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutta</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>S&#x000f6;derkvist</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gimm</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Genetics of primary hyperaldosteronism.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>R437</fpage>
            <page-range>R437-54</page-range>
            <pub-id pub-id-type="pmid">27485459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Fountain</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lappin</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <chapter-title>Physiology, Renin Angiotensin System</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">29261862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bokhari</surname>
                <given-names>SRA</given-names>
              </name>
              <name>
                <surname>Zulfiqar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mansur</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Bartter Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">28723048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Siddique</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chia</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Tay</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sogunuru</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kario</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Who should be screened for primary aldosteronism? A comprehensive review of current evidence.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>9</issue>
            <fpage>1194</fpage>
            <page-range>1194-1203</page-range>
            <pub-id pub-id-type="pmid">36196469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roth</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Mensah</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Addolorato</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ammirati</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baddour</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Barengo</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Beaton</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Benziger</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Bonny</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brodmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Carapetis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chugh</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Coresh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Criqui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeCleene</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Emmons-Bell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feigin</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Sol&#x000e0;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fowkes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gakidou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Inker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Karthikeyan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kassebaum</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koroshetz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lavie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Mirijello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Temesgen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mokdad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Narula</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ntsekhe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moraes de Oliveira</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Owolabi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rajagopalan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reitsma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>ALP</given-names>
              </name>
              <name>
                <surname>Rigotti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sable</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shakil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sliwa-Hahnle</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sundstr&#x000f6;m</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Timpel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tleyjeh</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Valgimigli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vos</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Yacoub</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zuhlke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fuster</surname>
                <given-names>V</given-names>
              </name>
              <collab>GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group</collab>
            </person-group>
            <article-title>Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2020</year>
            <month>Dec</month>
            <day>22</day>
            <volume>76</volume>
            <issue>25</issue>
            <fpage>2982</fpage>
            <page-range>2982-3021</page-range>
            <pub-id pub-id-type="pmid">33309175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Sakhuja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Apparent Treatment-Resistant Hypertension in the United States.</article-title>
            <source>Hypertension</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>424</fpage>
            <page-range>424-431</page-range>
            <pub-id pub-id-type="pmid">30580690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faconti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delles</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kapil</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Glover</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>IB</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society.</article-title>
            <source>J Hum Hypertens</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-18</page-range>
            <pub-id pub-id-type="pmid">37964158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strauch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zelinka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hampf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bernhardt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Widimsky</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region.</article-title>
            <source>J Hum Hypertens</source>
            <year>2003</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>349</fpage>
            <page-range>349-52</page-range>
            <pub-id pub-id-type="pmid">12756408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calhoun</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Nishizaka</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Zaman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Thakkar</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Weissmann</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hyperaldosteronism among black and white subjects with resistant hypertension.</article-title>
            <source>Hypertension</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>892</fpage>
            <page-range>892-6</page-range>
            <pub-id pub-id-type="pmid">12468575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turcu</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Nhan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grigoryan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Holevinski</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Primary Aldosteronism Screening Rates Differ with Sex, Race, and Comorbidities.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2022</year>
            <month>Jul</month>
            <day>19</day>
            <volume>11</volume>
            <issue>14</issue>
            <fpage>e025952</fpage>
            <pub-id pub-id-type="pmid">35861830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study.</article-title>
            <source>Ann Intern Med</source>
            <year>2020</year>
            <month>Jul</month>
            <day>07</day>
            <volume>173</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-20</page-range>
            <pub-id pub-id-type="pmid">32449886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yozamp</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Prevalence of Primary Aldosteronism and Evolving Approaches for Treatment.</article-title>
            <source>Curr Opin Endocr Metab Res</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>8</volume>
            <fpage>30</fpage>
            <page-range>30-39</page-range>
            <pub-id pub-id-type="pmid">32832727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Papadopoulou-Marketou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dluhy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperaldosteronism</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2020</year>
            <month>8</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">25905293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funder</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Mantero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2016</year>
            <month>May</month>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>1889</fpage>
            <page-range>1889-916</page-range>
            <pub-id pub-id-type="pmid">26934393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prejbisz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Warcho&#x00142;-Celi&#x00144;ska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Januszewicz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular Risk in Primary Hyperaldosteronism.</article-title>
            <source>Horm Metab Res</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>47</volume>
            <issue>13</issue>
            <fpage>973</fpage>
            <page-range>973-80</page-range>
            <pub-id pub-id-type="pmid">26575306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of primary aldosteronism: practical clinical perspectives.</article-title>
            <source>J Intern Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>285</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-148</page-range>
            <pub-id pub-id-type="pmid">30255616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Leppert</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Bhalla</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study.</article-title>
            <source>Ann Intern Med</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>174</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-297</page-range>
            <pub-id pub-id-type="pmid">33370170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000e4;yser</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Deinum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Grauw</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Schalk</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Bor</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Schermer</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Biermans</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of primary aldosteronism in primary care: a cross-sectional study.</article-title>
            <source>Br J Gen Pract</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>68</volume>
            <issue>667</issue>
            <fpage>e114</fpage>
            <page-range>e114-e122</page-range>
            <pub-id pub-id-type="pmid">29335324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulatero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Fardella</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Mosso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gomez-Sanchez</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Veglio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>89</volume>
            <issue>3</issue>
            <fpage>1045</fpage>
            <page-range>1045-50</page-range>
            <pub-id pub-id-type="pmid">15001583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moustaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paschou</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Vakali</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Vryonidou</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Secondary diabetes mellitus due to primary aldosteronism.</article-title>
            <source>Endocrine</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>79</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-30</page-range>
            <pub-id pub-id-type="pmid">36001240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luther</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Effects of aldosterone on insulin sensitivity and secretion.</article-title>
            <source>Steroids</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>91</volume>
            <fpage>54</fpage>
            <page-range>54-60</page-range>
            <pub-id pub-id-type="pmid">25194457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adler</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Turcu</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Nian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Solorzano</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Manning</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Luther</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Primary Aldosteronism Decreases Insulin Secretion and Increases Insulin Clearance in Humans.</article-title>
            <source>Hypertension</source>
            <year>2020</year>
            <month>May</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>1251</fpage>
            <page-range>1251-1259</page-range>
            <pub-id pub-id-type="pmid">32172621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Araujo-Castro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paja Fano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pla Peris</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez Boillos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pascual-Corrales</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Cano</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Parra Ram&#x000ed;rez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n Rojas-Marcos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruiz-Sanchez</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Vicente Delgado</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez Hoyos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Sanz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Recasens Sala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barahona San Millan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pic&#x000f3;n C&#x000e9;sar</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az Guardiola</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Perdomo</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Manj&#x000f3;n Migu&#x000e9;lez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Centeno</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Percovich</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Rebollo Rom&#x000e1;n</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Gracia Gimeno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Robles L&#x000e1;zaro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morales-Ruiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calatayud Guti&#x000e9;rrez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furio Collao</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Meneses</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sampedro Nu&#x000f1;ez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Escudero Quesada</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mena Ribas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sanmart&#x000ed;n S&#x000e1;nchez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonzalvo Diaz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lamas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guerrero-V&#x000e1;zquez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Del Castillo Tous</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serrano Gotarredona</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Michalopoulou Alevras</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moya Mateo</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hanzu</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>11</issue>
            <fpage>2343</fpage>
            <page-range>2343-2352</page-range>
            <pub-id pub-id-type="pmid">37037973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conn</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Rovner</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Landmark article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By Jerome W. Conn, Edwin L. Cohen and David R. Rovner.</article-title>
            <source>JAMA</source>
            <year>1985</year>
            <month>Jan</month>
            <day>25</day>
            <volume>253</volume>
            <issue>4</issue>
            <fpage>558</fpage>
            <page-range>558-66</page-range>
            <pub-id pub-id-type="pmid">3881606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gioco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Seccia</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gomez-Sanchez</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Gomez-Sanchez</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Adrenal histopathology in primary aldosteronism: is it time for a change?</article-title>
            <source>Hypertension</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>724</fpage>
            <page-range>724-30</page-range>
            <pub-id pub-id-type="pmid">26238443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r39">
          <label>39</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bokhari</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>SRA</given-names>
              </name>
            </person-group>
            <chapter-title>Renal Artery Stenosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">28613469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r40">
          <label>40</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Law</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tivakaran</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <chapter-title>Coarctation of the Aorta</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">28613663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r41">
          <label>41</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Parmar</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Muppidi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Gitelman Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">29083583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fagard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narkiewicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Redon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zanchetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Christiaens</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cifkova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dominiczak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Galderisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grobbee</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Jaarsma</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manolis</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Schmieder</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Sirnes</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Sleight</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Viigimaa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waeber</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Redon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dominiczak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Narkiewicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viigimaa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ambrosioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caufield</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Schmieder</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Tsioufis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van de Borne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Achenbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baumgartner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bax</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Deaton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fagard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hasdai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoes</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Knuuti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kolh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Linhart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nihoyannopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Piepoli</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sirnes</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Tamargo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Tendera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wijns</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clement</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Coca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gillebert</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Tendera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosei</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Ambrosioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hitij</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Caulfield</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Buyzere</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Geest</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Derumeaux</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Erdine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Farsang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Funck-Brentano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gerc</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Germano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gielen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hoes</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Komajda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mahrholdt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ostergren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Polonia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Popescu</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ryd&#x000e9;n</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sirenko</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Struijker-Boudier</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsioufis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van de Borne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vlachopoulos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Volpe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).</article-title>
            <source>Eur Heart J</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>28</issue>
            <fpage>2159</fpage>
            <page-range>2159-219</page-range>
            <pub-id pub-id-type="pmid">23771844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conroy</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Graves</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Menut</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Pearlstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Gosnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Screening for Primary Aldosteronism is Underutilized in Patients with Obstructive Sleep Apnea.</article-title>
            <source>Am J Med</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>135</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-66</page-range>
            <pub-id pub-id-type="pmid">34508708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chomsky-Higgins Menut</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pearlstein</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Conroy</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Gosnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.</article-title>
            <source>Surgery</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>171</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-103</page-range>
            <pub-id pub-id-type="pmid">34238603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Kao</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Jia-Yin Hou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Er</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Who needs to be screened for primary aldosteronism?</article-title>
            <source>J Formos Med Assoc</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>123 Suppl 2</volume>
            <fpage>S82</fpage>
            <page-range>S82-S90</page-range>
            <pub-id pub-id-type="pmid">37633770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Araujo-Castro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruiz-S&#x000e1;nchez</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Parra Ram&#x000ed;rez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n Rojas-Marcos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aguilera-Saborido</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez Cerezo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez Lazareno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Torregrosa Quesada</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Gorrin Ramos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oriola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Poch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oliveras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000e9;ndez Monter</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez Muriel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bella-Cueto</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Mercader Cidoncha</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Runkle</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hanzu</surname>
                <given-names>FA</given-names>
              </name>
              <collab>In representation of the following medical Spanish societies: Spanish Society of Endocrinology and Nutrition (SEEN), Spanish Society of Cardiology (SEC), Spanish Society of Nephrology (SEN), Spanish Society of Internal Medicine (SEMI), Spanish Radiology Society (SERAM), Spanish Society of Vascular and Interventional Radiology (SERVEI), Spanish Society of Laboratory Medicine (SEQC(ML), Spanish Society of Anatomic-Pathology, Spanish Association of Surgeons (AEC)</collab>
            </person-group>
            <article-title>Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism.</article-title>
            <source>Endocrine</source>
            <year>2024</year>
            <month>Jul</month>
            <volume>85</volume>
            <issue>1</issue>
            <fpage>99</fpage>
            <page-range>99-121</page-range>
            <pub-id pub-id-type="pmid">38448679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaffe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stedman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chertow</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Leppert</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Bhalla</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study.</article-title>
            <source>Hypertension</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>650</fpage>
            <page-range>650-659</page-range>
            <pub-id pub-id-type="pmid">32008436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruhle</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Alsafran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Angelos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Keeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives.</article-title>
            <source>Surgery</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>165</volume>
            <issue>1</issue>
            <fpage>221</fpage>
            <page-range>221-227</page-range>
            <pub-id pub-id-type="pmid">30415872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulatero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Monticone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burrello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Veglio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Funder</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for primary aldosteronism: uptake by primary care physicians in Europe.</article-title>
            <source>J Hypertens</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>11</issue>
            <fpage>2253</fpage>
            <page-range>2253-7</page-range>
            <pub-id pub-id-type="pmid">27607462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaidya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Evolution of the Primary Aldosteronism Syndrome: Updating the Approach.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Dec</month>
            <day>01</day>
            <volume>105</volume>
            <issue>12</issue>
            <fpage>3771</fpage>
            <page-range>3771-83</page-range>
            <pub-id pub-id-type="pmid">32865201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adlin</surname>
                <given-names>EV</given-names>
              </name>
            </person-group>
            <article-title>Subclinical Primary Aldosteronism.</article-title>
            <source>Ann Intern Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>07</day>
            <volume>167</volume>
            <issue>9</issue>
            <fpage>673</fpage>
            <page-range>673-674</page-range>
            <pub-id pub-id-type="pmid">29052700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Au-Yong</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Basnyat</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Sadler</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Review of surgical management of aldosterone secreting tumours of the adrenal cortex.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>467</fpage>
            <page-range>467-74</page-range>
            <pub-id pub-id-type="pmid">12798753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lubitz</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Economopoulos</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Sy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johanson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kunzel</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gazelle</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gaziano</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.</article-title>
            <source>Circ Cardiovasc Qual Outcomes</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>621</fpage>
            <page-range>621-30</page-range>
            <pub-id pub-id-type="pmid">26555126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>The aldosterone-renin ratio and primary aldosteronism.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>202</fpage>
            <page-range>202-3</page-range>
            <pub-id pub-id-type="pmid">11838659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veldhuizen</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Alnazer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Kroon</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>de Leeuw</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Variability of aldosterone, renin and the aldosterone-to-renin ratio in hypertensive patients without primary aldosteronism.</article-title>
            <source>J Hypertens</source>
            <year>2022</year>
            <month>Nov</month>
            <day>01</day>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>2256</fpage>
            <page-range>2256-2262</page-range>
            <pub-id pub-id-type="pmid">35950999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Island</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Liddle</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>A diurnal rhythm in plasma renin activity in man.</article-title>
            <source>J Clin Invest</source>
            <year>1966</year>
            <month>Oct</month>
            <volume>45</volume>
            <issue>10</issue>
            <fpage>1587</fpage>
            <page-range>1587-92</page-range>
            <pub-id pub-id-type="pmid">4288714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiu</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Shek</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>90</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-8</page-range>
            <pub-id pub-id-type="pmid">15483077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Calvird</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pimenta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>1039</fpage>
            <page-range>1039-45</page-range>
            <pub-id pub-id-type="pmid">21289246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wolley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McWhinney</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Ungerer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effect of Combined Hormonal Replacement Therapy on the Aldosterone/Renin Ratio in Postmenopausal Women.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2017</year>
            <month>Jul</month>
            <day>01</day>
            <volume>102</volume>
            <issue>7</issue>
            <fpage>2329</fpage>
            <page-range>2329-2334</page-range>
            <pub-id pub-id-type="pmid">28379474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grasso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boscaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scaroni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ceccato</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor.</article-title>
            <source>High Blood Press Cardiovasc Prev</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>345</fpage>
            <page-range>345-354</page-range>
            <pub-id pub-id-type="pmid">30415425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaidya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mulatero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baudrand</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.</article-title>
            <source>Endocr Rev</source>
            <year>2018</year>
            <month>Dec</month>
            <day>01</day>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>1057</fpage>
            <page-range>1057-1088</page-range>
            <pub-id pub-id-type="pmid">30124805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seccia</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Caroccia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gomez-Sanchez</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Gomez-Sanchez</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>The Biology of Normal Zona Glomerulosa and Aldosterone-Producing Adenoma: Pathological Implications.</article-title>
            <source>Endocr Rev</source>
            <year>2018</year>
            <month>Dec</month>
            <day>01</day>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>1029</fpage>
            <page-range>1029-1056</page-range>
            <pub-id pub-id-type="pmid">30007283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mosso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carvajal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barraza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Avila</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Montero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huete</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gederlini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fardella</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Primary aldosteronism and hypertensive disease.</article-title>
            <source>Hypertension</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-5</page-range>
            <pub-id pub-id-type="pmid">12796282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baguet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Steichen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mounier-V&#x000e9;hier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gosse</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA?</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-91</page-range>
            <pub-id pub-id-type="pmid">27087531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity.</article-title>
            <source>Clin Chem</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>386</fpage>
            <page-range>386-94</page-range>
            <pub-id pub-id-type="pmid">15681560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassirer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>WB</given-names>
              </name>
            </person-group>
            <article-title>On the pathogenesis of metabolic alkalosis in hyperaldosteronism.</article-title>
            <source>Am J Med</source>
            <year>1970</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>306</fpage>
            <page-range>306-15</page-range>
            <pub-id pub-id-type="pmid">5455562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanchard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiologic approach in genetic hypokalemia: An update.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>298</fpage>
            <page-range>298-307</page-range>
            <pub-id pub-id-type="pmid">36639120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Asano</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okazaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kano</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Renal potassium wasting in distal renal tubular acidosis: role of aldosterone.</article-title>
            <source>Intern Med</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>1047</fpage>
            <page-range>1047-51</page-range>
            <pub-id pub-id-type="pmid">1335804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaneko</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Umakoshi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishihara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nanba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuiki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kusakabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Satoh-Asahara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yasoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tagami</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Reassessment of Urinary Aldosterone Measurement After Saline Infusion in Primary Aldosteronism.</article-title>
            <source>J Endocr Soc</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>4</volume>
            <issue>9</issue>
            <fpage>bvaa100</fpage>
            <pub-id pub-id-type="pmid">32803096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>KD</given-names>
              </name>
              <collab>Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group</collab>
            </person-group>
            <article-title>Comparison of 24-h urinary aldosterone level and random urinary aldosterone-to-creatinine ratio in the diagnosis of primary aldosteronism.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>e67417</fpage>
            <pub-id pub-id-type="pmid">23840695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vilela</surname>
                <given-names>LAP</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>MQ</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of primary aldosteronism.</article-title>
            <source>Arch Endocrinol Metab</source>
            <year>2017</year>
            <season>May-Jun</season>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>305</fpage>
            <page-range>305-312</page-range>
            <pub-id pub-id-type="pmid">28699986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vakkalanka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Samannodi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Primary hyperaldosteronism: a case of unilateral adrenal hyperplasia with contralateral incidentaloma.</article-title>
            <source>BMJ Case Rep</source>
            <year>2016</year>
            <month>Jul</month>
            <day>14</day>
            <volume>2016</volume>
            <pub-id pub-id-type="pmid">27417992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dmitriev</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Secondary Hypertension Overview and Workup for the Primary Care Physician.</article-title>
            <source>Med Clin North Am</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>107</volume>
            <issue>4</issue>
            <fpage>739</fpage>
            <page-range>739-747</page-range>
            <pub-id pub-id-type="pmid">37258011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wrenn</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lubitz</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Primary aldosteronism.</article-title>
            <source>Gland Surg</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-24</page-range>
            <pub-id pub-id-type="pmid">32206595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reznik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Amar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tabarin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>202</fpage>
            <page-range>202-7</page-range>
            <pub-id pub-id-type="pmid">27318644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Confirmatory tests for the diagnosis of primary aldosteronism: A systematic review and meta-analysis.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2019</year>
            <month>May</month>
            <volume>90</volume>
            <issue>5</issue>
            <fpage>641</fpage>
            <page-range>641-648</page-range>
            <pub-id pub-id-type="pmid">30721529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piaditis</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Androulakis</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Gouli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Makras</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papadogias</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dimitriou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ragkou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Markou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vamvakidis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zografos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>772</fpage>
            <page-range>772-8</page-range>
            <pub-id pub-id-type="pmid">19226269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Primary aldosteronism.</article-title>
            <source>J Endocrinol Invest</source>
            <year>1995</year>
            <season>Jul-Aug</season>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>495</fpage>
            <page-range>495-511</page-range>
            <pub-id pub-id-type="pmid">9221268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klemm</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Tunny</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Primary aldosteronism--some genetic, morphological, and biochemical aspects of subtypes.</article-title>
            <source>Steroids</source>
            <year>1995</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-41</page-range>
            <pub-id pub-id-type="pmid">7792813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuller</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism.</article-title>
            <source>Clin Biochem Rev</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>111</fpage>
            <page-range>111-6</page-range>
            <pub-id pub-id-type="pmid">24353356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmiemann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gebhardt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hummers-Pradier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Egidi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of hyperaldosteronism in primary care patients with resistant hypertension.</article-title>
            <source>J Am Board Fam Med</source>
            <year>2012</year>
            <season>Jan-Feb</season>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>98</fpage>
            <page-range>98-103</page-range>
            <pub-id pub-id-type="pmid">22218630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gouli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tzonou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Markou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Androulakis</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Ragkou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vamvakidis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zografos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kontogeorgos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Piaditis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of autonomous aldosterone secretion among patients with essential hypertension.</article-title>
            <source>Eur J Clin Invest</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>1227</fpage>
            <page-range>1227-36</page-range>
            <pub-id pub-id-type="pmid">21534948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucatello</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabaro</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Capello</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caprino</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Marafetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rossato</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oleandri</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Ghigo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maccario</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>168</volume>
            <issue>4</issue>
            <fpage>525</fpage>
            <page-range>525-32</page-range>
            <pub-id pub-id-type="pmid">23321497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pappa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gouli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitsakis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsounas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Prevoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsiavos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Papanastasiou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zografos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Piaditis</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>1409</fpage>
            <page-range>1409-16</page-range>
            <pub-id pub-id-type="pmid">23471976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papanastasiou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Markou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pappa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gouli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsounas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fountoulakis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kounadi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsiama</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dasou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gryparis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Samara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zografos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Piaditis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Primary aldosteronism in hypertensive patients: clinical implications and target therapy.</article-title>
            <source>Eur J Clin Invest</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>8</issue>
            <fpage>697</fpage>
            <page-range>697-706</page-range>
            <pub-id pub-id-type="pmid">24909545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klemm</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Tunny</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Plasma aldosterone response to ACTH in subtypes of primary aldosteronism.</article-title>
            <source>Clin Exp Pharmacol Physiol</source>
            <year>1995</year>
            <season>Jun-Jul</season>
            <volume>22</volume>
            <issue>6-7</issue>
            <fpage>460</fpage>
            <page-range>460-2</page-range>
            <pub-id pub-id-type="pmid">8582103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gleason</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Weinberger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bihrle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dugan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Donohue</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia.</article-title>
            <source>J Urol</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>150</volume>
            <issue>5 Pt 1</issue>
            <fpage>1365</fpage>
            <page-range>1365-8</page-range>
            <pub-id pub-id-type="pmid">8411401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aronova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fahey</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Zarnegar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Management of hypertension in primary aldosteronism.</article-title>
            <source>World J Cardiol</source>
            <year>2014</year>
            <month>May</month>
            <day>26</day>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>227</fpage>
            <page-range>227-33</page-range>
            <pub-id pub-id-type="pmid">24944753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiner</surname>
                <given-names>ID</given-names>
              </name>
            </person-group>
            <article-title>Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.</article-title>
            <source>Semin Nephrol</source>
            <year>2013</year>
            <month>May</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>265</fpage>
            <page-range>265-76</page-range>
            <pub-id pub-id-type="pmid">23953804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harvey</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Hyperaldosteronism: diagnosis, lateralization, and treatment.</article-title>
            <source>Surg Clin North Am</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>643</fpage>
            <page-range>643-56</page-range>
            <pub-id pub-id-type="pmid">24857581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quencer</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Adrenal vein sampling: technique and protocol, a systematic review.</article-title>
            <source>CVIR Endovasc</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <pub-id pub-id-type="pmid">33939038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kobayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alkukhun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Salaskar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Adrenal Vein Sampling: Tips and Tricks.</article-title>
            <source>Radiographics</source>
            <year>2024</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>e230115</fpage>
            <pub-id pub-id-type="pmid">38662586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Auchus</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plouin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism.</article-title>
            <source>Hypertension</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>151</fpage>
            <page-range>151-60</page-range>
            <pub-id pub-id-type="pmid">24218436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasternak</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Epelboym</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Seiser</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wingo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gosnell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Kerlan</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic utility of data from adrenal venous sampling for primary aldosteronism despite failed cannulation of the right adrenal vein.</article-title>
            <source>Surgery</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>159</volume>
            <issue>1</issue>
            <fpage>267</fpage>
            <page-range>267-73</page-range>
            <pub-id pub-id-type="pmid">26435431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Can incomplete adrenal venous sampling data be used in predicting the subtype of primary aldosteronism?</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>80</volume>
            <issue>5-6</issue>
            <fpage>301</fpage>
            <page-range>301-307</page-range>
            <pub-id pub-id-type="pmid">31722788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burrello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burrello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pieroni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sconfienza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Forestiero</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Amongero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rossato</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Veglio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Monticone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mulatero</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>183</volume>
            <issue>6</issue>
            <fpage>657</fpage>
            <page-range>657-667</page-range>
            <pub-id pub-id-type="pmid">33112264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Hwu</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Strategies for subtyping primary aldosteronism.</article-title>
            <source>J Formos Med Assoc</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>123 Suppl 2</volume>
            <fpage>S114</fpage>
            <page-range>S114-S124</page-range>
            <pub-id pub-id-type="pmid">37202237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Martino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Sanz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz de Nova</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Mar&#x000ed;n Campos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez Mart&#x000ed;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dom&#x000ed;nguez Gadea</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>NP-59 test for preoperative localization of primary hyperaldosteronism.</article-title>
            <source>Langenbecks Arch Surg</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>402</volume>
            <issue>2</issue>
            <fpage>303</fpage>
            <page-range>303-308</page-range>
            <pub-id pub-id-type="pmid">28224279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsutomo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kono</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of standardized uptake value on <sup>131</sup>I-6&#x003b2;-iodomethyl-19-norcholesterol scintigraphy for diagnosis of primary aldosteronism and correspondence with adrenal venous sampling.</article-title>
            <source>Ann Nucl Med</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-98</page-range>
            <pub-id pub-id-type="pmid">36380175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spyridonidis</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Apostolopoulos</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Is there a role for Nuclear Medicine in diagnosis and management of patients with primary aldosteronism?</article-title>
            <source>Hell J Nucl Med</source>
            <year>2013</year>
            <season>May-Aug</season>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>134</fpage>
            <page-range>134-9</page-range>
            <pub-id pub-id-type="pmid">23865085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O' Doherty</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O' Doherty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robins</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Reilhac</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Parametric mapping for 11C-metomidate PET-computed tomography imaging in the study of primary aldosteronism.</article-title>
            <source>Nucl Med Commun</source>
            <year>2021</year>
            <month>Aug</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">34406144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puar</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>AKT</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>MCS</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Reilhac</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Doherty</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gomez-Sanchez</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kek</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>AWK</given-names>
              </name>
              <name>
                <surname>Chuah</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DHM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>CQ</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Robins</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Foo</surname>
                <given-names>RSY</given-names>
              </name>
              <collab>for the PA CURE investigators</collab>
            </person-group>
            <article-title>11C-Metomidate PET-CT versus adrenal vein sampling to subtype primary aldosteronism: a prospective clinical trial.</article-title>
            <source>J Hypertens</source>
            <year>2022</year>
            <month>Jun</month>
            <day>01</day>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>1179</fpage>
            <page-range>1179-1188</page-range>
            <pub-id pub-id-type="pmid">35703880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Chueh</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Yen</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>VC</given-names>
              </name>
              <collab>Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group</collab>
            </person-group>
            <article-title>Predicting Treatment Response in Primary Aldosteronism Using 11 C-Metomidate Positron Emission Tomography.</article-title>
            <source>Clin Nucl Med</source>
            <year>2022</year>
            <month>Nov</month>
            <day>01</day>
            <volume>47</volume>
            <issue>11</issue>
            <fpage>936</fpage>
            <page-range>936-942</page-range>
            <pub-id pub-id-type="pmid">36215396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Senanayake</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goodchild</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bashari</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Salsbury</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cabrera</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Argentesi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>O'Toole</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Matson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Parvanta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kosmoliaptsis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berney</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Foo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mein</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Wozniak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sahdev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Laycock</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Boros</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hader</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Warnes</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gillett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dawnay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adeyeye</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Prete</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Arlt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bhuva</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Aigbirhio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manisty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McIntosh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McConnachie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cruickshank</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Cheow</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gurnell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drake</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>[<sup>11</sup>C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial.</article-title>
            <source>Nat Med</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>190</fpage>
            <page-range>190-202</page-range>
            <pub-id pub-id-type="pmid">36646800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bartsch</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>[<sup>11</sup>C-metomidate PET-CT vs. selective adrenal vein sampling for prediction of surgical success in primary aldosteronism : Results of the prospective MATCH study].</article-title>
            <source>Chirurgie (Heidelb)</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>94</volume>
            <issue>10</issue>
            <fpage>877</fpage>
            <page-range>877-878</page-range>
            <pub-id pub-id-type="pmid">37682281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <collab>Chongqing Primary Aldosteronism Study (CONPASS) Group</collab>
            </person-group>
            <article-title>Accuracy of Gallium-68 Pentixafor Positron Emission Tomography-Computed Tomography for Subtyping Diagnosis of Primary Aldosteronism.</article-title>
            <source>JAMA Netw Open</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>e2255609</fpage>
            <pub-id pub-id-type="pmid">36795418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wolley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Schewe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>St&#x000f6;lting</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scholl</surname>
                <given-names>UI</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2019</year>
            <month>Apr</month>
            <day>04</day>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>31</fpage>
            <pub-id pub-id-type="pmid">30949771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corssmit</surname>
                <given-names>EPM</given-names>
              </name>
              <name>
                <surname>Dekkers</surname>
                <given-names>OM</given-names>
              </name>
            </person-group>
            <article-title>Screening in adrenal tumors.</article-title>
            <source>Curr Opin Oncol</source>
            <year>2019</year>
            <month>May</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>243</fpage>
            <page-range>243-246</page-range>
            <pub-id pub-id-type="pmid">30844886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chikladze</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Favorova</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Chazova</surname>
                <given-names>IE</given-names>
              </name>
            </person-group>
            <article-title>Family hyperaldosteronism type I: a clinical case and review of literature.</article-title>
            <source>Ter Arkh</source>
            <year>2018</year>
            <month>Sep</month>
            <day>20</day>
            <volume>90</volume>
            <issue>9</issue>
            <fpage>115</fpage>
            <page-range>115-122</page-range>
            <pub-id pub-id-type="pmid">30701745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pons Fern&#x000e1;ndez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Morata</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moriano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le&#x000f3;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Mingo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zu&#x000f1;iga</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Familial hyperaldosteronism type III a novel case and review of literature.</article-title>
            <source>Rev Endocr Metab Disord</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-36</page-range>
            <pub-id pub-id-type="pmid">30569443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruedgam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adolf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schwarzlmueller</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Handgriff</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bidlingmaier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Deniz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Beuschlein</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heinrich</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Postoperative ACTH-stimulated aldosterone predicts biochemical outcome in primary aldosteronism.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2023</year>
            <month>Dec</month>
            <day>06</day>
            <volume>189</volume>
            <issue>6</issue>
            <fpage>611</fpage>
            <page-range>611-618</page-range>
            <pub-id pub-id-type="pmid">38048424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>ZW</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chueh</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <collab>TAIPAI Study Group</collab>
            </person-group>
            <article-title>Reversal of arterial stiffness in medically and surgically treated unilateral primary aldosteronism.</article-title>
            <source>J Hypertens</source>
            <year>2024</year>
            <month>Mar</month>
            <day>01</day>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>538</fpage>
            <page-range>538-545</page-range>
            <pub-id pub-id-type="pmid">38088428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Rossitto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Amar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Azizi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riester</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Degenhart</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Widimsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Deinum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schultze Kool</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kocjan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Negro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Christian Rump</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vonend</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Willenberg</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chee</surname>
                <given-names>NYN</given-names>
              </name>
              <name>
                <surname>Magill</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Shafigullina</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Quinkler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oliveras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dun Wu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Kratka</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Barbiero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Battistel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Vanderriele</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Pessina</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling.</article-title>
            <source>Hypertension</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>800</fpage>
            <page-range>800-808</page-range>
            <pub-id pub-id-type="pmid">31476901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vesel&#x000fd;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Spironolactone in the treatment of hypertension: a neglected molecule].</article-title>
            <source>Vnitr Lek</source>
            <year>2018</year>
            <season>Fall</season>
            <volume>64</volume>
            <issue>7-8</issue>
            <fpage>815</fpage>
            <page-range>815-820</page-range>
            <pub-id pub-id-type="pmid">30441987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Mulatero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>10 good reasons why adrenal vein sampling is the preferred method for referring primary aldosteronism patients for adrenalectomy.</article-title>
            <source>J Hypertens</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>603</fpage>
            <page-range>603-611</page-range>
            <pub-id pub-id-type="pmid">30431526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>179</volume>
            <issue>1</issue>
            <fpage>R19</fpage>
            <page-range>R19-R29</page-range>
            <pub-id pub-id-type="pmid">29674485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r118">
          <label>118</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patibandla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kyaw</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <chapter-title>Spironolactone</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">32119308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r119">
          <label>119</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Hughes</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Cassagnol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Eplerenone</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31971740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>The outcomes of transcatheter adrenal ablation in patients with primary aldosteronism: a systematic review and meta-analysis.</article-title>
            <source>BMC Endocr Disord</source>
            <year>2023</year>
            <month>May</month>
            <day>08</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <pub-id pub-id-type="pmid">37150817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacks</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Sacks</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Faintuch</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Radiofrequency ablation treatment for aldosterone-producing adenomas.</article-title>
            <source>Curr Opin Endocrinol Diabetes Obes</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>169</fpage>
            <page-range>169-173</page-range>
            <pub-id pub-id-type="pmid">28248752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Retroperitoneoscopic-guided cool-tip radiofrequency ablation of adrenocortical aldosteronoma.</article-title>
            <source>J Endourol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1208</fpage>
            <page-range>1208-14</page-range>
            <pub-id pub-id-type="pmid">24935642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouhanick</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Delchier</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lagarde</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boulestreau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Conil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gosse</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rousseau</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lepage</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Olivier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Trillaud</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cremer</surname>
                <given-names>A</given-names>
              </name>
              <collab>for the ADERADHTA group</collab>
            </person-group>
            <article-title>Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study.</article-title>
            <source>J Hypertens</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>759</fpage>
            <page-range>759-765</page-range>
            <pub-id pub-id-type="pmid">33196558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r124">
          <label>124</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oguro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ota</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yanagaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kawabata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kamada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Omata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tezuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morimoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Toyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tanimoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Konno</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yamauchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niwa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishihata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takase</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Transvenous Radiofrequency Catheter Ablation for an Aldosterone-Producing Tumor of the Left Adrenal Gland: A First in Human Case Report.</article-title>
            <source>Cardiovasc Intervent Radiol</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>1666</fpage>
            <page-range>1666-1673</page-range>
            <pub-id pub-id-type="pmid">37973663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r125">
          <label>125</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oguro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morimoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seiji</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ota</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawabata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Omata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tezuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moriya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Omura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakatsuka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurihara</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miyashita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koda</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Minami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kometani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ushio</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goshima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takase</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Safety and feasibility of radiofrequency ablation using bipolar electrodes for aldosterone-producing adenoma: a multicentric prospective clinical study.</article-title>
            <source>Sci Rep</source>
            <year>2022</year>
            <month>Aug</month>
            <day>18</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>14090</fpage>
            <pub-id pub-id-type="pmid">35982148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r126">
          <label>126</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Adrenalectomy for primary aldosteronism and its related surgical characteristics.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2024</year>
            <volume>15</volume>
            <fpage>1416287</fpage>
            <pub-id pub-id-type="pmid">38966219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r127">
          <label>127</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Li</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Dream</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Adrenalectomy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">32644519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r128">
          <label>128</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parthasarathy</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>M&#x000e9;nard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Connell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.</article-title>
            <source>J Hypertens</source>
            <year>2011</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>980</fpage>
            <page-range>980-90</page-range>
            <pub-id pub-id-type="pmid">21451421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r129">
          <label>129</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samnani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cenzer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hundemer</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>McClurg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pasieka</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Boscardin</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Ronksley</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2024</year>
            <month>Feb</month>
            <day>20</day>
            <volume>109</volume>
            <issue>3</issue>
            <fpage>e1280</fpage>
            <page-range>e1280-e1289</page-range>
            <pub-id pub-id-type="pmid">37946600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r130">
          <label>130</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lyu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Asghar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of bilateral superselective adrenal arterial embolization for treatment of idiopathic hyperaldosteronism: a prospective single-center study.</article-title>
            <source>BMC Surg</source>
            <year>2024</year>
            <month>Aug</month>
            <day>24</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>242</fpage>
            <pub-id pub-id-type="pmid">39182043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r131">
          <label>131</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial.</article-title>
            <source>Catheter Cardiovasc Interv</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>97 Suppl 2</volume>
            <fpage>976</fpage>
            <page-range>976-981</page-range>
            <pub-id pub-id-type="pmid">33605538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r132">
          <label>132</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Adrenal Ablation Versus Mineralocorticoid Receptor Antagonism for the Treatment of Primary Aldosteronism: A Single-Center Prospective Cohort Study.</article-title>
            <source>Am J Hypertens</source>
            <year>2022</year>
            <month>Dec</month>
            <day>08</day>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>1014</fpage>
            <page-range>1014-1023</page-range>
            <pub-id pub-id-type="pmid">36205513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r133">
          <label>133</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Accumulating evidence suggests the potential of selective adrenal artery embolization as a standard treatment for primary aldosteronism.</article-title>
            <source>Hypertens Res</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>1744</fpage>
            <page-range>1744-1746</page-range>
            <pub-id pub-id-type="pmid">38538840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r134">
          <label>134</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yokota</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Adrenal arterial embolization: a possible new treatment for patients with primary aldosteronism.</article-title>
            <source>Hypertens Res</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>358</fpage>
            <page-range>358-360</page-range>
            <pub-id pub-id-type="pmid">37828135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r135">
          <label>135</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A controlled trial of percutaneous adrenal arterial embolization for hypertension in patients with idiopathic hyperaldosteronism.</article-title>
            <source>Hypertens Res</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>311</fpage>
            <page-range>311-321</page-range>
            <pub-id pub-id-type="pmid">37644179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r136">
          <label>136</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mai</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kometani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoneda</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Nov</month>
            <day>10</day>
            <volume>23</volume>
            <issue>22</issue>
            <pub-id pub-id-type="pmid">36430298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r137">
          <label>137</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matlaga</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Assimos</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced urinary calculi.</article-title>
            <source>Rev Urol</source>
            <year>2003</year>
            <season>Fall</season>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>227</fpage>
            <page-range>227-31</page-range>
            <pub-id pub-id-type="pmid">16985842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r138">
          <label>138</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daudon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jungers</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced renal calculi: epidemiology, prevention and management.</article-title>
            <source>Drugs</source>
            <year>2004</year>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>245</fpage>
            <page-range>245-75</page-range>
            <pub-id pub-id-type="pmid">14871169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r139">
          <label>139</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carr</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Prien</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Babayan</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Triamterene nephrolithiasis: renewed attention is warranted.</article-title>
            <source>J Urol</source>
            <year>1990</year>
            <month>Dec</month>
            <volume>144</volume>
            <issue>6</issue>
            <fpage>1339</fpage>
            <page-range>1339-40</page-range>
            <pub-id pub-id-type="pmid">2231920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r140">
          <label>140</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dooley</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Callsen</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Geiling</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Triamterene nephrolithiasis.</article-title>
            <source>Mil Med</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>154</volume>
            <issue>3</issue>
            <fpage>126</fpage>
            <page-range>126-7</page-range>
            <pub-id pub-id-type="pmid">2496337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r141">
          <label>141</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Niyazov</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharman</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <chapter-title>Triamterene</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">32491582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r142">
          <label>142</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armanini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sabbadin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Don&#x000e0;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Clari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bordin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2014</year>
            <month>May</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>909</fpage>
            <page-range>909-12</page-range>
            <pub-id pub-id-type="pmid">24617854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r143">
          <label>143</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cerny</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Progress towards clinically useful aldosterone synthase inhibitors.</article-title>
            <source>Curr Top Med Chem</source>
            <year>2013</year>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>1385</fpage>
            <page-range>1385-401</page-range>
            <pub-id pub-id-type="pmid">23688131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r144">
          <label>144</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernhardt</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The potential of targeting CYP11B.</article-title>
            <source>Expert Opin Ther Targets</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>923</fpage>
            <page-range>923-34</page-range>
            <pub-id pub-id-type="pmid">26854589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r145">
          <label>145</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism.</article-title>
            <source>Acta Pharm Sin B</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>135</fpage>
            <page-range>135-148</page-range>
            <pub-id pub-id-type="pmid">35127376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r146">
          <label>146</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funder</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Primary Aldosteronism: The Next Five Years.</article-title>
            <source>Horm Metab Res</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>12</issue>
            <fpage>977</fpage>
            <page-range>977-983</page-range>
            <pub-id pub-id-type="pmid">29065433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r147">
          <label>147</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kline</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Prebtani</surname>
                <given-names>APH</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Schiffrin</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Primary aldosteronism: a common cause of resistant hypertension.</article-title>
            <source>CMAJ</source>
            <year>2017</year>
            <month>Jun</month>
            <day>05</day>
            <volume>189</volume>
            <issue>22</issue>
            <fpage>E773</fpage>
            <page-range>E773-E778</page-range>
            <pub-id pub-id-type="pmid">28584041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r148">
          <label>148</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mar&#x000ed;n-Mart&#x000ed;nez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>R&#x000ed;os-Vergara</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kyriakos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez-Mart&#x000ed;n</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Alonso</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Bilateral Adrenalectomy in a Patient With Refractory Primary Aldosteronism Due to Adrenal Hyperplasia.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>e24267</fpage>
            <pub-id pub-id-type="pmid">35607563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r149">
          <label>149</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Effects of a low-sodium diet in patients with idiopathic hyperaldosteronism: a randomized controlled trial.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1124479</fpage>
            <pub-id pub-id-type="pmid">37152926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r150">
          <label>150</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akkus</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Two Cases with 17-alpha Hydroxylase Deficiency Misdiagnosed as Primary Aldosteronism.</article-title>
            <source>Endocr Metab Immune Disord Drug Targets</source>
            <year>2023</year>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1449</fpage>
            <page-range>1449-1454</page-range>
            <pub-id pub-id-type="pmid">37032508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r151">
          <label>151</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Chormanski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Muzio</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <chapter-title>17-Hydroxylase Deficiency</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31536251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r152">
          <label>152</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schiffrin</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Chr&#x000e9;tien</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seidah</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Lis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gutkowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cantin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Genest</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Response of human aldosteronoma cells in culture to the N-terminal glycopeptide of pro-opiomelanocortin and gamma 3-MSH.</article-title>
            <source>Horm Metab Res</source>
            <year>1983</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>181</fpage>
            <page-range>181-4</page-range>
            <pub-id pub-id-type="pmid">6862354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r153">
          <label>153</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Momodu</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <chapter-title>Congenital Adrenal Hyperplasia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">28846271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r154">
          <label>154</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guia Lopes</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Limbert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sequeira Duarte</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Rare Cause of Cushing's Syndrome: an Adrenocorticotropic Hormone (ACTH)-Secreting Pheochromocytoma.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>e37883</fpage>
            <pub-id pub-id-type="pmid">37223141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r155">
          <label>155</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birtolo</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Grossrubatscher</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Antonini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mazziotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lania</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Chiodini</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Preoperative management of patients with ectopic Cushing's syndrome caused by ACTH-secreting pheochromocytoma: a case series and review of the literature.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>10</issue>
            <fpage>1983</fpage>
            <page-range>1983-1994</page-range>
            <pub-id pub-id-type="pmid">37195583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r156">
          <label>156</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanko&#x000e7;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x0015e;at&#x00131;r T&#x000fc;rk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000d6;zkan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sayan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000c7;elik</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Typical Carcinoid Tumor Cases Causing Ectopic ACTH Syndrome: Dramatic Response to Surgery.</article-title>
            <source>Port J Card Thorac Vasc Surg</source>
            <year>2023</year>
            <month>Apr</month>
            <day>04</day>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-56</page-range>
            <pub-id pub-id-type="pmid">37029946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r157">
          <label>157</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golounina</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Belaya</surname>
                <given-names>ZE</given-names>
              </name>
              <name>
                <surname>Rozhinskaya</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Pikunov</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Markovich</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Dzeranova</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Marova</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Kuznetsov</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Fadeev</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Melnichenko</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Dedov</surname>
                <given-names>II</given-names>
              </name>
            </person-group>
            <article-title>[Survival predictors in patients with ectopic acth syndrome].</article-title>
            <source>Probl Endokrinol (Mosk)</source>
            <year>2022</year>
            <month>Aug</month>
            <day>15</day>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>30</fpage>
            <page-range>30-42</page-range>
            <pub-id pub-id-type="pmid">36689709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r158">
          <label>158</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Iqbal</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jamal</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <chapter-title>Essential Hypertension</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30969681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r159">
          <label>159</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabbadin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Armanini</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Syndromes that Mimic an Excess of Mineralocorticoids.</article-title>
            <source>High Blood Press Cardiovasc Prev</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-5</page-range>
            <pub-id pub-id-type="pmid">27251484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r160">
          <label>160</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bangert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kluge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Janneck</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Life-Threatening Complications of Excessive Licorice Consumption.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2021</year>
            <month>Dec</month>
            <day>27</day>
            <volume>118</volume>
            <issue>51-52</issue>
            <fpage>890</fpage>
            <page-range>890-891</page-range>
            <pub-id pub-id-type="pmid">35321787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r161">
          <label>161</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mubarik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anastasopoulou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <chapter-title>Liddle Syndrome (Pseudohyperaldosteronism)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">30725596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r162">
          <label>162</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms of glucocorticoid resistance.</article-title>
            <source>Eur J Clin Invest</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>e13901</fpage>
            <pub-id pub-id-type="pmid">36346177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r163">
          <label>163</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolaides</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Charmandari</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Primary Generalized Glucocorticoid Resistance and Hypersensitivity Syndromes: A 2021 Update.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>Oct</month>
            <day>07</day>
            <volume>22</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">34639183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r164">
          <label>164</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nicolaides</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Charmandari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <chapter-title>Primary Generalized Glucocorticoid Resistance Syndrome</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">25905168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r165">
          <label>165</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Harbi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Al-Shaikh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Apparent mineralocorticoid excess syndrome: report of one family with three affected children.</article-title>
            <source>J Pediatr Endocrinol Metab</source>
            <year>2012</year>
            <volume>25</volume>
            <issue>11-12</issue>
            <fpage>1083</fpage>
            <page-range>1083-8</page-range>
            <pub-id pub-id-type="pmid">23329753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r166">
          <label>166</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stavropoulos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Imprialos</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Patoulias</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Katsimardou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Doumas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Impact of Primary Aldosteronism in Resistant Hypertension.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>285</fpage>
            <page-range>285-294</page-range>
            <pub-id pub-id-type="pmid">35445928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r167">
          <label>167</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Auchus</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and Treatment of Patients With Hypercortisolism: A Review.</article-title>
            <source>JAMA Surg</source>
            <year>2020</year>
            <month>Dec</month>
            <day>01</day>
            <volume>155</volume>
            <issue>12</issue>
            <fpage>1152</fpage>
            <page-range>1152-1159</page-range>
            <pub-id pub-id-type="pmid">33052413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r168">
          <label>168</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buffolo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mulatero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Monticone</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Aldosterone as a Mediator of Cardiovascular Damage.</article-title>
            <source>Hypertension</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>79</volume>
            <issue>9</issue>
            <fpage>1899</fpage>
            <page-range>1899-1911</page-range>
            <pub-id pub-id-type="pmid">35766038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r169">
          <label>169</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mandal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dutta</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Unique Case of Cardiomyopathy Secondary to Adrenal Adenoma (Primary-Aldosteronism).</article-title>
            <source>J Assoc Physicians India</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>71</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">37116014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r170">
          <label>170</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Primary aldosteronism presenting as embolic myocardial infarction.</article-title>
            <source>Neuro Endocrinol Lett</source>
            <year>2022</year>
            <month>Sep</month>
            <day>16</day>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>140</fpage>
            <page-range>140-144</page-range>
            <pub-id pub-id-type="pmid">36179724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r171">
          <label>171</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Mamauag</surname>
                <given-names>MJB</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saffari</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Aw</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Foo</surname>
                <given-names>RSY</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Fones</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Puar</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>869980</fpage>
            <pub-id pub-id-type="pmid">35518929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r172">
          <label>172</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakaguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Akao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kamemura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kurihara</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Inagaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rakugi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Katabami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsuiki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dohi</surname>
                <given-names>K</given-names>
              </name>
              <collab>JRAS investigators</collab>
              <name>
                <surname>Naruse</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Associated factors and effects of comorbid atrial fibrillation in hypertensive patients due to primary aldosteronism.</article-title>
            <source>J Hum Hypertens</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>757</fpage>
            <page-range>757-766</page-range>
            <pub-id pub-id-type="pmid">36153382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r173">
          <label>173</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>CMR-Verified Myocardial Fibrosis Is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>672557</fpage>
            <pub-id pub-id-type="pmid">34054733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r174">
          <label>174</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Chueh</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>KD</given-names>
              </name>
              <collab>TAIPAI Study Group</collab>
            </person-group>
            <article-title>Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism.</article-title>
            <source>J Hypertens</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>8</issue>
            <fpage>1606</fpage>
            <page-range>1606-13</page-range>
            <pub-id pub-id-type="pmid">22688266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r175">
          <label>175</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Primary aldosteronism and obstructive sleep apnea: A meta-analysis of prevalence and metabolic characteristics.</article-title>
            <source>Sleep Med</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>114</volume>
            <fpage>8</fpage>
            <page-range>8-14</page-range>
            <pub-id pub-id-type="pmid">38142557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r176">
          <label>176</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Bernini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caliumi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Desideri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fabris</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ferri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ganzaroli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giacchetti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Letizia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maccario</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mallamaci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mannelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mattarello</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Moretti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Parenti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Porteri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Semplicini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rizzoni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boscaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pessina</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Mantero</surname>
                <given-names>F</given-names>
              </name>
              <collab>PAPY Study Investigators</collab>
            </person-group>
            <article-title>A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2006</year>
            <month>Dec</month>
            <day>05</day>
            <volume>48</volume>
            <issue>11</issue>
            <fpage>2293</fpage>
            <page-range>2293-300</page-range>
            <pub-id pub-id-type="pmid">17161262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r177">
          <label>177</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000fc;pers</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Amar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Raynaud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Plouin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Steichen</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>A clinical prediction score to diagnose unilateral primary aldosteronism.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>97</volume>
            <issue>10</issue>
            <fpage>3530</fpage>
            <page-range>3530-7</page-range>
            <pub-id pub-id-type="pmid">22918872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r178">
          <label>178</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Chueh</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CC</given-names>
              </name>
              <collab>TAIPAI Study Group</collab>
            </person-group>
            <article-title>Machine Learning Model with Computed Tomography Radiomics and Clinicobiochemical Characteristics Predict the Subtypes of Patients with Primary Aldosteronism.</article-title>
            <source>Acad Radiol</source>
            <year>2024</year>
            <month>May</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>1818</fpage>
            <page-range>1818-1827</page-range>
            <pub-id pub-id-type="pmid">38042624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r179">
          <label>179</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mansour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mittermeier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schachtner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rudolph</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Erber</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Heinrich</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bruedgam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tschaidse</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nowotny</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bidlingmaier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Adolf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ricke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reisch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wildgruber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ingrisch</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Integration of clinical parameters and CT-based radiomics improves machine learning assisted subtyping of primary hyperaldosteronism.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1244342</fpage>
            <pub-id pub-id-type="pmid">37693351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r180">
          <label>180</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karashima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kawakami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nambo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kometani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurihara</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ichijo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katabami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsuiki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Inagaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yoshimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kakutani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Izawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suwa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamemura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoneda</surname>
                <given-names>T</given-names>
              </name>
              <collab>JPAS/JRAS Study Group</collab>
            </person-group>
            <article-title>A hyperaldosteronism subtypes predictive model using ensemble learning.</article-title>
            <source>Sci Rep</source>
            <year>2023</year>
            <month>Feb</month>
            <day>21</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>3043</fpage>
            <pub-id pub-id-type="pmid">36810868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r181">
          <label>181</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A new machine learning-based prediction model for subtype diagnosis in primary aldosteronism.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>1005934</fpage>
            <pub-id pub-id-type="pmid">36506080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r182">
          <label>182</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Constantinescu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schulze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peitzsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hofmockel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Scholl</surname>
                <given-names>UI</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JWM</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Integration of artificial intelligence and plasma steroidomics with laboratory information management systems: application to primary aldosteronism.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2022</year>
            <month>Nov</month>
            <day>25</day>
            <volume>60</volume>
            <issue>12</issue>
            <fpage>1929</fpage>
            <page-range>1929-1937</page-range>
            <pub-id pub-id-type="pmid">35851438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23092.r183">
          <label>183</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hundemer</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Pasieka</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Przybojewski</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Caughlin</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>External Validation of Clinical Prediction Models in Unilateral Primary Aldosteronism.</article-title>
            <source>Am J Hypertens</source>
            <year>2022</year>
            <month>Apr</month>
            <day>02</day>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>365</fpage>
            <page-range>365-373</page-range>
            <pub-id pub-id-type="pmid">34958097</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
